{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":9514,"total_is_capped":false,"direct_labels_cover":106,"predictions_cover":9514,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"11ee7dc1d95b","filters":{"venue":"Journal of Clinical Oncology"}},"results":[{"id":"W2133201432","doi":"10.1200/jco.2006.09.2403","title":"Revised Response Criteria for Malignant Lymphoma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4448,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Medical physics; Harmonization; Lymphoma; Positron emission tomography; Clinical trial; Oncology; Internal medicine; Nuclear medicine","authors":[{"name":"Bruce D. Cheson","is_ca":true},{"name":"Beate Pfistner","is_ca":true},{"name":"Malik E. Juweid","is_ca":true},{"name":"Randy D. Gascoyne","is_ca":true},{"name":"Lena Specht","is_ca":true},{"name":"Sandra J. Horning","is_ca":true},{"name":"Bertrand Coiffier","is_ca":true},{"name":"Richard I. Fisher","is_ca":true},{"name":"Anton Hagenbeek","is_ca":true},{"name":"Emanuele Zucca","is_ca":true},{"name":"Steven T. Rosen","is_ca":true},{"name":"Sigrid Stroobants","is_ca":true},{"name":"T. Andrew Lister","is_ca":true},{"name":"Richard T. Hoppe","is_ca":true},{"name":"Martin Dreyling","is_ca":true},{"name":"Kensei Tobinai","is_ca":true},{"name":"Julie M. Vose","is_ca":true},{"name":"Joseph M. Connors","is_ca":true},{"name":"Massimo Federico","is_ca":true},{"name":"Volker Diehl","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1830828747671805,"gpt":0.5290861835862772,"spread":0.3460033088190968,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0784127,0.002511393,0.004696464,0.007710959,0.001706459,0.003101275,0.006449028,0.004360908,0.006949934],"category_scores_gemma":[0.09782093,0.0006707138,0.00672071,0.004477134,0.002578981,0.003707387,0.003890877,0.008178664,0.005762811],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006217912,"about_ca_system_score_gemma":0.006100678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003286296,"about_ca_topic_score_gemma":0.003247024,"domain_scores_codex":[0.897711,0.06286055,0.02315446,0.001937819,0.01115875,0.003177307],"domain_scores_gemma":[0.8893087,0.03626845,0.01780577,0.006607343,0.04723364,0.002776067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.008510418,0.0003905535,0.03868923,0.01797661,0.00170066,0.001692649,0.001576619,0.006863595,0.004546064,0.03421665,0.5056272,0.3782098],"study_design_scores_gemma":[0.003804662,0.002567251,0.06032448,0.006930949,0.001643498,0.008511525,0.0007312206,0.005897026,0.002852892,0.01913749,0.8872559,0.0003431335],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"methods","genre_scores_codex":[0.03930579,0.2856462,0.2645077,0.1555477,0.02475842,0.05965846,0.03542451,0.004836665,0.1303146],"genre_scores_gemma":[0.2913231,0.04286766,0.4054031,0.05730931,0.01066288,0.09664845,0.0613884,0.00191624,0.03248079],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.0784127,"threshold_uncertainty_score":0.414691,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137853125","doi":"10.1200/jco.2009.25.6529","title":"American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4267,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Oncology; Estrogen receptor; Guideline; Internal medicine; Progesterone receptor; Cancer; Estrogen; Immunohistochemistry; Gynecology; Pathology","authors":[{"name":"M. Elizabeth H. Hammond","is_ca":false},{"name":"Daniel F. Hayes","is_ca":false},{"name":"Mitch Dowsett","is_ca":false},{"name":"D. Craig Allred","is_ca":false},{"name":"Karen L. Hagerty","is_ca":false},{"name":"Sunil Badve","is_ca":false},{"name":"Patrick L. Fitzgibbons","is_ca":false},{"name":"Glenn Francis","is_ca":false},{"name":"Neil S. Goldstein","is_ca":false},{"name":"Malcolm Hayes","is_ca":false},{"name":"David G. Hicks","is_ca":false},{"name":"Susan C. Lester","is_ca":false},{"name":"Richard R. Love","is_ca":false},{"name":"Pamela B. Mangu","is_ca":false},{"name":"Lisa M. McShane","is_ca":false},{"name":"Keith Miller","is_ca":false},{"name":"C. Kent Osborne","is_ca":false},{"name":"Soonmyung Paik","is_ca":false},{"name":"Jane Perlmutter","is_ca":false},{"name":"Anthony Rhodes","is_ca":false},{"name":"Hironobu Sasano","is_ca":false},{"name":"Jared N. Schwartz","is_ca":false},{"name":"Fred C.G.J. Sweep","is_ca":false},{"name":"Sheila E. Taube","is_ca":false},{"name":"Emina Torlakovic","is_ca":false},{"name":"Paul N. Valenstein","is_ca":false},{"name":"Giuseppe Viale","is_ca":false},{"name":"Daniel W. Visscher","is_ca":false},{"name":"Thomas M. Wheeler","is_ca":false},{"name":"Roger Williams","is_ca":false},{"name":"James L. Wittliff","is_ca":false},{"name":"Antonio C. Wolff","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1044654445549377,"gpt":0.4879802130540102,"spread":0.3835147684990725,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02043211,0.001575214,0.002223716,0.007545416,0.002060045,0.001900829,0.007397382,0.007735025,0.004051688],"category_scores_gemma":[0.04412302,0.0009962816,0.003639222,0.005774522,0.001846445,0.001574882,0.002131453,0.009752263,0.004983078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005002916,"about_ca_system_score_gemma":0.02186481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03124991,"about_ca_topic_score_gemma":0.04715003,"domain_scores_codex":[0.9764251,0.009686914,0.004871686,0.0005966728,0.007439691,0.0009801207],"domain_scores_gemma":[0.9286979,0.0128472,0.004762198,0.001464862,0.0495561,0.002671793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001000129,0.0002569908,0.00355248,0.002743401,0.0001156219,0.0008409541,0.0003898572,0.0009888168,0.001151193,0.003670078,0.8338292,0.1523614],"study_design_scores_gemma":[0.0004844157,0.0002549492,0.02130655,0.01731062,0.0006400236,0.004152508,0.0009115289,0.002616697,0.001442552,0.01182168,0.9388779,0.0001807068],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.01129063,0.1146254,0.1135961,0.543406,0.02570521,0.02301959,0.01283588,0.002057232,0.153464],"genre_scores_gemma":[0.03610045,0.0925177,0.630975,0.1448416,0.005760753,0.02260163,0.02683433,0.00056924,0.03979931],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.03124991,"threshold_uncertainty_score":0.1080567,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2158134441","doi":"10.1200/jco.2006.07.9525","title":"Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3859,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Gemcitabine; Erlotinib; Medicine; Internal medicine; Pancreatic cancer; Erlotinib Hydrochloride; Oncology; Hazard ratio; Adverse effect; Placebo; Clinical endpoint; Clinical trial; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","authors":[{"name":"Malcolm J. Moore","is_ca":true},{"name":"David Goldstein","is_ca":true},{"name":"John Hamm","is_ca":true},{"name":"Arié Figer","is_ca":true},{"name":"J. Randolph Hecht","is_ca":true},{"name":"Steven Gallinger","is_ca":true},{"name":"H. Au","is_ca":true},{"name":"P. Murawa","is_ca":true},{"name":"David Walde","is_ca":true},{"name":"Robert A. Wolff","is_ca":true},{"name":"Daniel de Castro","is_ca":true},{"name":"Robert Lim","is_ca":true},{"name":"Keyue Ding","is_ca":true},{"name":"Gary M. Clark","is_ca":true},{"name":"Theodora Voskoglou-Nomikos","is_ca":true},{"name":"Mieke Ptasynski","is_ca":true},{"name":"Wendy R. Parulekar","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1918460886647593,"gpt":0.5307549424111981,"spread":0.3389088537464388,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002142933,0.001383767,0.002514711,0.0003634211,0.0004914634,0.001025081,0.0007437323,0.001168112,0.003962142],"category_scores_gemma":[0.001650099,0.0003822498,0.001830694,0.0006228651,0.0008236529,0.0005502077,0.0002907834,0.002722772,0.0004280246],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002074574,"about_ca_system_score_gemma":0.003125771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01235901,"about_ca_topic_score_gemma":0.03469945,"domain_scores_codex":[0.9993296,0.0004143563,0.00003309946,0.00007912843,0.00006105463,0.00008271658],"domain_scores_gemma":[0.9992016,0.0001756368,0.0002415586,0.00004334639,0.00007440384,0.0002633851],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.963687,0.003850208,0.0007559969,0.0008219967,0.001223996,0.0000275436,0.00004489414,0.0005148456,0.001115337,0.00009094241,0.001902594,0.02596453],"study_design_scores_gemma":[0.9451656,0.04748755,0.004217052,0.00008084467,0.0009051238,0.00004291937,0.00002458792,0.0005818898,0.0002506364,0.00009438945,0.001131741,0.00001765442],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9667326,0.01973854,0.0004343408,0.002313145,0.0006893711,0.004119412,0.001813912,0.0001026756,0.004056045],"genre_scores_gemma":[0.9770571,0.01073498,0.001431223,0.001668544,0.000502573,0.002839301,0.001476339,0.00002058365,0.004269349],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01235901,"threshold_uncertainty_score":0.02457416,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2143743735","doi":"10.1200/jco.2007.14.9930","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2963,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Capecitabine; Clinical endpoint; Chemotherapy; Placebo; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","authors":[{"name":"Leonard B. Saltz","is_ca":true},{"name":"Stephen Clarke","is_ca":true},{"name":"Eduardo Díaz‐Rubio","is_ca":true},{"name":"Werner Scheithauer","is_ca":true},{"name":"Arié Figer","is_ca":true},{"name":"Ralph Wong","is_ca":true},{"name":"Sheryl Koski","is_ca":true},{"name":"Mikhail Lichinitser","is_ca":true},{"name":"Tsai‐Shen Yang","is_ca":true},{"name":"Fernando Rivera","is_ca":true},{"name":"Félix Couture","is_ca":true},{"name":"Florin Sirzén","is_ca":true},{"name":"Jim Cassidy","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1003262096290122,"gpt":0.4668804551886769,"spread":0.3665542455596647,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002346284,0.001454065,0.003273105,0.0005358372,0.0003781448,0.001301826,0.001022422,0.00173196,0.00411129],"category_scores_gemma":[0.001700549,0.0007831574,0.001544145,0.000614836,0.001124878,0.0008167692,0.0003863775,0.002349879,0.0007631545],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001122926,"about_ca_system_score_gemma":0.00165285,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009825545,"about_ca_topic_score_gemma":0.002858041,"domain_scores_codex":[0.999006,0.0006085928,0.00004933999,0.0001287725,0.00009596658,0.0001114261],"domain_scores_gemma":[0.9990342,0.0002167275,0.0002555952,0.0000693472,0.00006744283,0.0003567423],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9409665,0.02153045,0.0009437883,0.0008912999,0.001393293,0.00007729983,0.00004971489,0.0005513667,0.005887782,0.00008662324,0.0009600062,0.02666187],"study_design_scores_gemma":[0.8990873,0.09830515,0.0009934601,0.00003007661,0.0003524858,0.00003540347,0.000007860916,0.0003702179,0.000298949,0.00004549448,0.0004647953,0.0000088584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834124,0.007655781,0.0008734933,0.0007160083,0.0006110051,0.004603819,0.0006331938,0.0001228493,0.001371464],"genre_scores_gemma":[0.9800152,0.006176476,0.002342877,0.001245621,0.0007899663,0.006121652,0.001052889,0.0000340009,0.002221186],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00411129,"threshold_uncertainty_score":0.01375365,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2984359187","doi":"10.1200/jco.19.02105","title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":2963,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Pembrolizumab; Medicine; Microsatellite instability; Cancer; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; DNA mismatch repair; Phases of clinical research; Gastroenterology; Immunotherapy; Toxicity; Clinical trial; Colorectal cancer","authors":[{"name":"Aurélien Marabelle","is_ca":false},{"name":"Dung T. Le","is_ca":false},{"name":"Paolo A. Ascierto","is_ca":false},{"name":"Anna Maria Di Giacomo","is_ca":false},{"name":"Ana De Jesus‐Acosta","is_ca":false},{"name":"Jean-Pierre Delord","is_ca":false},{"name":"Ravit Geva","is_ca":false},{"name":"Maya Gottfried","is_ca":false},{"name":"Nicolas Penel","is_ca":false},{"name":"Aaron R. Hansen","is_ca":true},{"name":"Sarina A. Piha‐Paul","is_ca":false},{"name":"Toshihiko Doi","is_ca":false},{"name":"Bo Gao","is_ca":false},{"name":"Hyun Cheol Chung","is_ca":false},{"name":"José A. López-Martín","is_ca":false},{"name":"Yung-Jue Bang","is_ca":false},{"name":"Ronnie Shapira Frommer","is_ca":false},{"name":"Manisha H. Shah","is_ca":false},{"name":"Razi Ghori","is_ca":false},{"name":"Andrew K. Joe","is_ca":false},{"name":"Scott K. Pruitt","is_ca":false},{"name":"Luis A. Díaz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05014804818147979,"gpt":0.4084384987829472,"spread":0.3582904506014675,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001491236,0.0006421636,0.0008234309,0.0001581331,0.0002072132,0.0004895147,0.0003448504,0.0005255115,0.0009753078],"category_scores_gemma":[0.0009922014,0.0002327674,0.0006691741,0.0002078954,0.0002771729,0.0004067272,0.0001536068,0.001071732,0.000253982],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005866957,"about_ca_system_score_gemma":0.0005892975,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004218559,"about_ca_topic_score_gemma":0.0009456105,"domain_scores_codex":[0.9997638,0.0001162215,0.00002067229,0.00003847014,0.00002761287,0.00003323637],"domain_scores_gemma":[0.9994895,0.0001328644,0.0001460486,0.00003829803,0.00004078612,0.0001524094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.455592,0.0383581,0.1570368,0.00187362,0.003898946,0.0008690109,0.0007118505,0.004038215,0.1028622,0.0002966048,0.006485541,0.2279771],"study_design_scores_gemma":[0.2858892,0.3590974,0.3259356,0.0001945181,0.002919602,0.00209446,0.0002310361,0.004023002,0.01182658,0.0002004155,0.00753035,0.00005772445],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962708,0.002292935,0.000194565,0.0001335621,0.00001591249,0.0002316363,0.0003158303,0.00001567377,0.0005290848],"genre_scores_gemma":[0.9968818,0.001013188,0.0004691761,0.0002321452,0.00004001441,0.0001965891,0.0009180845,0.000005391615,0.0002435569],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001491236,"threshold_uncertainty_score":0.007886469,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2104504726","doi":"10.1200/jco.2007.13.9030","title":"Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2670,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology; Les Laboratories Pierre Fabre; Sanofi; GlaxoSmithKline; Eli Lilly and Company","keywords":"Medicine; Vinorelbine; Internal medicine; Vinca; Chemotherapy; Etoposide; Hazard ratio; Vinca alkaloid; Cisplatin; Lung cancer; Oncology; Stage (stratigraphy); Vindesine; Clinical trial; Confidence interval; Pharmacology; Cyclophosphamide; Vincristine","authors":[{"name":"Jean‐Pierre Pignon","is_ca":true},{"name":"Hélène Tribodet","is_ca":true},{"name":"Giorgio V. Scagliotti","is_ca":true},{"name":"Jean-Yves Douillard","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Richard Stephens","is_ca":true},{"name":"Ariane Dunant","is_ca":true},{"name":"Valter Torri","is_ca":true},{"name":"Rafael Rosell","is_ca":true},{"name":"Lesley Seymour","is_ca":true},{"name":"Stephen Spiro","is_ca":true},{"name":"Estelle Rolland","is_ca":true},{"name":"Roldano Fossati","is_ca":true},{"name":"D. Aubert","is_ca":true},{"name":"Keyue Ding","is_ca":true},{"name":"David Waller","is_ca":true},{"name":"Thierry Le Chevalier","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09634526887575641,"gpt":0.4933364237251135,"spread":0.3969911548493571,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02148564,0.002194438,0.01314914,0.003460081,0.0003177738,0.002572146,0.001137265,0.00163841,0.002419513],"category_scores_gemma":[0.03239349,0.0007670691,0.02748395,0.003313693,0.0005803337,0.001283724,0.001797878,0.001484323,0.0003410807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00231091,"about_ca_system_score_gemma":0.002712161,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00686607,"about_ca_topic_score_gemma":0.01526213,"domain_scores_codex":[0.9790127,0.01446187,0.002356225,0.001784716,0.00198371,0.0004007552],"domain_scores_gemma":[0.9869606,0.006378303,0.003637097,0.001357601,0.001351755,0.0003146176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.04888889,0.00006446381,0.009066478,0.04626662,0.8558251,0.00008707575,0.0000495856,0.001832632,0.0004650885,0.0002088153,0.004196439,0.03304888],"study_design_scores_gemma":[0.04757084,0.001630997,0.01799728,0.005509593,0.9206378,0.0001113581,0.0000307697,0.0007037534,0.0002610963,0.0003727638,0.005093298,0.00008034992],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.06591947,0.9161747,0.003395759,0.00168346,0.0006948265,0.002543603,0.007098652,0.0001781503,0.002311334],"genre_scores_gemma":[0.7513832,0.2201945,0.0063469,0.00536806,0.001085731,0.004857889,0.008361279,0.0001952266,0.00220711],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02148564,"threshold_uncertainty_score":0.1136283,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2118558111","doi":"10.1200/jco.2012.45.2722","title":"Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":2658,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"University of New Brunswick","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Underweight; Body mass index; Overweight; Obesity paradox; Cachexia; Weight loss; Internal medicine; Cancer; Obesity; Skeletal muscle; Lung cancer; Univariate analysis; Multivariate analysis","authors":[{"name":"Lisa Martin","is_ca":true},{"name":"Laura Birdsell","is_ca":true},{"name":"Neil Macdonald","is_ca":true},{"name":"Tony Reiman","is_ca":true},{"name":"M. Thomas Clandinin","is_ca":true},{"name":"Linda J. McCargar","is_ca":true},{"name":"Rachel A. Murphy","is_ca":true},{"name":"Sunita Ghosh","is_ca":true},{"name":"Michael B. Sawyer","is_ca":true},{"name":"Vickie E. Baracos","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1179012815893561,"gpt":0.4682270623116528,"spread":0.3503257807222967,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005376516,0.0002962174,0.0002391126,0.0004312694,0.0003111665,0.0003994809,0.0002870169,0.0003316506,0.000621953],"category_scores_gemma":[0.002468226,0.0001168919,0.0001621072,0.0004721453,0.0004850749,0.0001936591,0.000293195,0.0003910728,0.0001149744],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003577501,"about_ca_system_score_gemma":0.0006765334,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01785358,"about_ca_topic_score_gemma":0.03059225,"domain_scores_codex":[0.9998337,0.00004568709,0.00001127864,0.00002174924,0.00005601095,0.00003148655],"domain_scores_gemma":[0.9987771,0.0002389844,0.0005466563,0.00006064004,0.0001600525,0.0002166942],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00009267614,0.000006073982,0.9984681,0.000004379989,0.00001464232,0.00003311265,0.00001047638,0.00004205738,0.0001825938,0.000004286511,0.000043148,0.001098391],"study_design_scores_gemma":[0.00000410442,0.00006474651,0.9989261,0.000006036025,0.00002851857,0.0003069883,0.00003992338,0.0004238986,0.00006797189,0.00002041648,0.000109239,0.000002092013],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986016,0.0007910749,0.0001270584,0.000103088,0.000006419952,0.000005543493,0.00007983092,0.000004351934,0.0002811037],"genre_scores_gemma":[0.9996106,0.0001234799,0.00007658653,0.00001546601,0.00001194272,0.000001493114,0.0000991436,6.350051e-7,0.00006070829],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01785358,"threshold_uncertainty_score":0.03549933,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2134667653","doi":"10.1200/jco.2004.08.163","title":"Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2433,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Neutropenia; Internal medicine; Lung cancer; Febrile neutropenia; Chemotherapy; Regimen; Dexamethasone; Chemotherapy regimen; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cisplatin","authors":[{"name":"Nasser H. Hanna","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Frank V. Fossella","is_ca":true},{"name":"Jose R. Pereira","is_ca":true},{"name":"Filippo de Marinis","is_ca":true},{"name":"Joachim von Pawel","is_ca":true},{"name":"U. Gatzemeier","is_ca":true},{"name":"Thomas Chang Yao Tsao","is_ca":true},{"name":"Miklos Pless","is_ca":true},{"name":"Thomas Müller","is_ca":true},{"name":"Hong-Liang Lim","is_ca":true},{"name":"Christopher E. Desch","is_ca":true},{"name":"Klára Szondy","is_ca":true},{"name":"Radj Gervais","is_ca":true},{"name":"Shaharyar","is_ca":false},{"name":"Christian Manegold","is_ca":true},{"name":"Sofia Paul","is_ca":true},{"name":"Paolo Paoletti","is_ca":true},{"name":"Lawrence Einhorn","is_ca":true},{"name":"Paul A. Bunn","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04615425508884495,"gpt":0.4591494644487017,"spread":0.4129952093598567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001968741,0.001310727,0.00312402,0.0003221378,0.0004210578,0.00108935,0.0009420526,0.001388888,0.006109369],"category_scores_gemma":[0.002451515,0.000562157,0.001408646,0.0004018697,0.001161486,0.000768688,0.0003650796,0.003487931,0.0008884273],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00121542,"about_ca_system_score_gemma":0.001676932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001340627,"about_ca_topic_score_gemma":0.003910386,"domain_scores_codex":[0.9992388,0.0004827712,0.00004236995,0.00008993032,0.00004835709,0.00009771642],"domain_scores_gemma":[0.9986021,0.0004308763,0.0003281351,0.00007835119,0.00006552789,0.0004950899],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9799119,0.006102925,0.0006539093,0.0002953559,0.0006209585,0.00003526683,0.00004164692,0.0004147287,0.00125871,0.0000875375,0.0007849089,0.009792116],"study_design_scores_gemma":[0.954416,0.04315466,0.001101837,0.00001902607,0.0001642248,0.00002685776,0.00001194811,0.000374937,0.0001596432,0.00007647184,0.0004892893,0.00000513953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837309,0.004631059,0.0006156828,0.001130142,0.001003537,0.005531143,0.0009456283,0.0001082164,0.002303592],"genre_scores_gemma":[0.9843363,0.002566028,0.001246986,0.001644026,0.0004581412,0.0057751,0.001057122,0.0000210005,0.002895429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006109369,"threshold_uncertainty_score":0.02043784,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2116760308","doi":"10.1200/jco.2009.25.9820","title":"Metastatic Behavior of Breast Cancer Subtypes","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2284,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Basal (medicine); Internal medicine; Oncology; Cancer; Pathology; Lung cancer; Lung; Metastasis; Stage (stratigraphy); Biology","authors":[{"name":"Hagen F. Kennecke","is_ca":true},{"name":"Rinat Yerushalmi","is_ca":true},{"name":"Ryan Woods","is_ca":true},{"name":"Maggie C.U. Cheang","is_ca":true},{"name":"David Voduc","is_ca":true},{"name":"Caroline Speers","is_ca":true},{"name":"Torsten O. Nielsen","is_ca":true},{"name":"Karen A. Gelmon","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06226160108180336,"gpt":0.4550223279959653,"spread":0.392760726914162,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002471063,0.0001728678,0.0001493258,0.0004336195,0.00020239,0.0003216312,0.0001521627,0.0002064689,0.001536772],"category_scores_gemma":[0.001297352,0.00008168056,0.0002074748,0.0002894008,0.0001007461,0.0001335473,0.0001909238,0.0001931728,0.0003216429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003724699,"about_ca_system_score_gemma":0.0001557606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003417901,"about_ca_topic_score_gemma":0.005328466,"domain_scores_codex":[0.9998702,0.00002757287,0.00001019008,0.00002838812,0.00003279722,0.0000309048],"domain_scores_gemma":[0.9995322,0.00008860389,0.000200656,0.00002506546,0.00007189095,0.00008158658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003525519,0.00001795257,0.9850552,0.00002909849,0.00004504945,0.0005412695,0.00007182068,0.0003697562,0.0023627,0.0001098382,0.0003203062,0.01072446],"study_design_scores_gemma":[0.00001714805,0.00007626799,0.9910352,0.00002464081,0.00004358834,0.005823512,0.0001032623,0.0007218894,0.000749713,0.0002644787,0.001133532,0.000006784331],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964331,0.001638502,0.000192145,0.00006434075,0.000003995573,0.000009189464,0.0003746738,0.000006988982,0.001276904],"genre_scores_gemma":[0.9989237,0.0002499318,0.0001090026,0.00001246744,0.000006351546,0.000004027186,0.0003783447,0.00000283077,0.000313301],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003417901,"threshold_uncertainty_score":0.006796002,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099088585","doi":"10.1200/jco.2008.20.1293","title":"Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2189,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Pfizer Canada; Genentech; GlaxoSmithKline; American Society of Clinical Oncology; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Hazard ratio; Discontinuation; Alpha interferon; Adverse effect; Clinical endpoint; Gastroenterology; Log-rank test; Progression-free survival; Oncology; Urology; Proportional hazards model; Randomized controlled trial; Confidence interval; Interferon; Overall survival; Immunology","authors":[{"name":"Robert J. Motzer","is_ca":false},{"name":"Thomas E. Hutson","is_ca":false},{"name":"Piotr Tomczak","is_ca":false},{"name":"M. Dror Michaelson","is_ca":false},{"name":"Ronald M. Bukowski","is_ca":false},{"name":"Stéphane Oudard","is_ca":false},{"name":"Sylvie Négrier","is_ca":false},{"name":"Cezary Szczylik","is_ca":false},{"name":"Роберто Пили","is_ca":false},{"name":"Georg A. Bjarnason","is_ca":false},{"name":"Xavier García del Muro","is_ca":false},{"name":"Jeffrey A. Sosman","is_ca":false},{"name":"E Solska","is_ca":false},{"name":"George Wilding","is_ca":false},{"name":"John A. Thompson","is_ca":false},{"name":"Sindy T. Kim","is_ca":false},{"name":"Isan Chen","is_ca":false},{"name":"Xin Huang","is_ca":false},{"name":"Robert A. Figlin","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1019284234891843,"gpt":0.387397130270231,"spread":0.2854687067810467,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002276477,0.0004674793,0.001210196,0.0002419173,0.0001940795,0.0005515926,0.0003125574,0.00046901,0.001654634],"category_scores_gemma":[0.002309037,0.0001551999,0.001682736,0.0002807314,0.0002371314,0.0003777179,0.000202722,0.00109095,0.0002020027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005688097,"about_ca_system_score_gemma":0.0004701593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005738072,"about_ca_topic_score_gemma":0.001513624,"domain_scores_codex":[0.9991072,0.0004887452,0.0000727001,0.0001031754,0.0001600563,0.00006818609],"domain_scores_gemma":[0.9985365,0.0005348324,0.0005688823,0.00007188402,0.0001147385,0.0001731808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.675386,0.001892891,0.07353703,0.002035528,0.01029095,0.0002305151,0.0001569448,0.003780112,0.007732028,0.0001529756,0.004041505,0.2207637],"study_design_scores_gemma":[0.184882,0.2041999,0.5589572,0.0004649495,0.02666723,0.00158803,0.0001372208,0.00631946,0.00730718,0.0005366979,0.008842248,0.00009790665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9751652,0.0219363,0.0003928032,0.0004681314,0.0001485081,0.0001099799,0.0007248135,0.00003443786,0.0010197],"genre_scores_gemma":[0.9944589,0.00280952,0.0002939753,0.0003495261,0.0001826625,0.00009480191,0.001288572,0.000007393316,0.0005146036],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002276477,"threshold_uncertainty_score":0.0120393,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099752220","doi":"10.1200/jco.2008.21.4809","title":"Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2130,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Bevacizumab; Sorafenib; Proportional hazards model; Cohort; Adverse effect; Oncology; Vascular endothelial growth factor; Cancer; Gastroenterology; Hepatocellular carcinoma; Chemotherapy; VEGF receptors","authors":[{"name":"Daniel Y.C. Heng","is_ca":false},{"name":"Wanling Xie","is_ca":false},{"name":"Meredith M. Regan","is_ca":false},{"name":"Mark Warren","is_ca":false},{"name":"Ali Golshayan","is_ca":false},{"name":"Chakshu Sahi","is_ca":false},{"name":"Bernhard J. Eigl","is_ca":false},{"name":"Joseph D. Ruether","is_ca":false},{"name":"Tina Cheng","is_ca":false},{"name":"Scott North","is_ca":false},{"name":"Peter Venner","is_ca":false},{"name":"Jennifer J. Knox","is_ca":false},{"name":"Kim N.","is_ca":false},{"name":"Christian Kollmannsberger","is_ca":false},{"name":"David F. McDermott","is_ca":false},{"name":"William Oh","is_ca":false},{"name":"Michael B. Atkins","is_ca":false},{"name":"Ronald M. Bukowski","is_ca":false},{"name":"Brian I. Rini","is_ca":false},{"name":"Toni K. Choueiri","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07369899872305304,"gpt":0.3582692181119489,"spread":0.2845702193888959,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001367429,0.0003400795,0.0005173013,0.0003993868,0.0003651087,0.0005037923,0.0003642246,0.0002782487,0.000598735],"category_scores_gemma":[0.002527563,0.0001392773,0.0005412839,0.0009400841,0.0002945929,0.0002822856,0.0003118077,0.0003770228,0.000141796],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006368798,"about_ca_system_score_gemma":0.0008203021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008210338,"about_ca_topic_score_gemma":0.009156501,"domain_scores_codex":[0.9993982,0.0002212528,0.00004340092,0.0001469677,0.0001345756,0.00005554801],"domain_scores_gemma":[0.9980433,0.0003068834,0.0008323842,0.0001646661,0.0002941073,0.0003586333],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000558398,0.00005224622,0.9968862,0.00001166538,0.0001998951,0.000040592,0.00003396401,0.00006567258,0.0002553287,0.000005900884,0.0001771574,0.001712925],"study_design_scores_gemma":[0.00007142778,0.0001804973,0.9989448,0.000004701411,0.000102709,0.0001406555,0.00004351349,0.0001813365,0.00006780936,0.000009748716,0.0002488815,0.000003883759],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9987801,0.0004857113,0.00008640884,0.00005198881,0.000005257628,0.0000120888,0.0004520279,0.000003961308,0.0001224873],"genre_scores_gemma":[0.9989523,0.0001375898,0.00008806596,0.00003175306,0.00001995037,0.00001281889,0.0007126934,0.000002084675,0.00004274114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008210338,"threshold_uncertainty_score":0.01632506,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2103257412","doi":"10.1200/jco.2005.07.757","title":"Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1854,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinblastine; Gemcitabine; Internal medicine; Transitional cell carcinoma; Hazard ratio; Cisplatin; Bladder cancer; Urology; Oncology; Methotrexate; Chemotherapy; Doxorubicin; Antimetabolite; Progression-free survival; Gastroenterology; Cancer; Confidence interval","authors":[{"name":"Hans von der Maase","is_ca":true},{"name":"Lisa Sengeløv","is_ca":true},{"name":"J.T. Roberts","is_ca":true},{"name":"Sergio Ricci","is_ca":true},{"name":"Luigi Dogliotti","is_ca":true},{"name":"T. Oliver","is_ca":true},{"name":"Malcolm J. Moore","is_ca":true},{"name":"Annamaria H. Zimmermann","is_ca":true},{"name":"M. Arning","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08192046514609955,"gpt":0.4237490158951968,"spread":0.3418285507490972,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003043329,0.0008680269,0.001827206,0.0002922046,0.0003853238,0.000979998,0.0006171871,0.001440414,0.002462124],"category_scores_gemma":[0.00346346,0.0004281078,0.002420832,0.0003001058,0.0007944563,0.0007929455,0.0004048211,0.00240788,0.000300066],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001111477,"about_ca_system_score_gemma":0.001087805,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007310295,"about_ca_topic_score_gemma":0.001965514,"domain_scores_codex":[0.9981474,0.00135245,0.0001204657,0.0001859684,0.00008012372,0.0001137727],"domain_scores_gemma":[0.9975044,0.0009711172,0.0006778459,0.0001390212,0.0001097081,0.0005979434],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9825565,0.002501072,0.001637439,0.0003268479,0.001633352,0.00002297127,0.00002847982,0.0005207606,0.000859187,0.00003492657,0.0002396615,0.009638892],"study_design_scores_gemma":[0.8860928,0.1021277,0.007282881,0.00007755151,0.002596631,0.00005033808,0.0000239682,0.0007603118,0.0004030885,0.000127669,0.0004396329,0.00001738221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930079,0.004939945,0.0002239018,0.0004366622,0.0002263126,0.0004905653,0.0001980288,0.00001734971,0.0004592475],"genre_scores_gemma":[0.9965616,0.001228222,0.0003586896,0.0004441883,0.0001926542,0.0004841783,0.0003665687,0.000005326459,0.000358518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003043329,"threshold_uncertainty_score":0.0160948,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2990602950","doi":"10.1200/jco.19.01307","title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1819,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Placebo; Hazard ratio; Internal medicine; Sorafenib; Interim analysis; Adverse effect; Population; Randomized controlled trial; Intention-to-treat analysis; Hepatocellular carcinoma; Subgroup analysis; Surgery; Gastroenterology; Confidence interval; Cancer; Immunotherapy; Pathology","authors":[{"name":"Richard S. Finn","is_ca":false},{"name":"Baek‐Yeol Ryoo","is_ca":false},{"name":"Philippe Merle","is_ca":false},{"name":"Masatoshi Kudo","is_ca":false},{"name":"Mohamed Bouattour","is_ca":false},{"name":"Ho Yeong Lim","is_ca":false},{"name":"В. В. Бредер","is_ca":false},{"name":"Julien Edeline","is_ca":false},{"name":"Yee Chao","is_ca":false},{"name":"Sadahisa Ogasawara","is_ca":false},{"name":"Thomas Yau","is_ca":false},{"name":"Marcelo Garrido","is_ca":false},{"name":"Stephen L. Chan","is_ca":false},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Bruno Daniele","is_ca":false},{"name":"Scot Ebbinghaus","is_ca":false},{"name":"Erluo Chen","is_ca":false},{"name":"Abby B. Siegel","is_ca":false},{"name":"Andrew X. Zhu","is_ca":false},{"name":"Ann‐Lii Cheng","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1234301453155467,"gpt":0.4015304858931631,"spread":0.2781003405776164,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002329075,0.00121961,0.001883647,0.0003662102,0.0004050321,0.001087159,0.0006869346,0.001258256,0.003840646],"category_scores_gemma":[0.001301859,0.0004753803,0.001243592,0.0003717969,0.0007908436,0.0008658069,0.0004130345,0.001994303,0.0008403267],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006315209,"about_ca_system_score_gemma":0.001084671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000321178,"about_ca_topic_score_gemma":0.0007032272,"domain_scores_codex":[0.999351,0.00033127,0.00005208142,0.0001105704,0.00005723791,0.0000979176],"domain_scores_gemma":[0.999348,0.000116095,0.0001635014,0.00005771978,0.00003883947,0.000275953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9390175,0.01548942,0.00134782,0.0008867689,0.0007714414,0.00009313909,0.00007549261,0.0004330517,0.007794334,0.0001775535,0.001662659,0.03225075],"study_design_scores_gemma":[0.9369054,0.05951969,0.001516531,0.00002407547,0.0002334655,0.00007185098,0.00001161553,0.0002619704,0.0006664487,0.00006846998,0.0007115534,0.000009024297],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834327,0.006044195,0.0007320098,0.0006860858,0.0003814118,0.00550145,0.001054156,0.0001397249,0.002028245],"genre_scores_gemma":[0.9865154,0.002871353,0.00143433,0.001116479,0.0004585371,0.004954473,0.001034038,0.00001588231,0.001599482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003840646,"threshold_uncertainty_score":0.01284826,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2910245285","doi":"10.1200/jco.18.00149","title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1716,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Internal medicine; Hazard ratio; Oncology; Tolerability; Clinical endpoint; Chemotherapy regimen; Surgery; Cancer; Confidence interval; Randomized controlled trial; Immunotherapy; Adverse effect","authors":[{"name":"Martin Reck","is_ca":false},{"name":"Delvys Rodríguez‐Abreu","is_ca":false},{"name":"Andrew Robinson","is_ca":true},{"name":"Rina Hui","is_ca":false},{"name":"Tibor Csőszi","is_ca":false},{"name":"Andrea Fülöp","is_ca":false},{"name":"Maya Gottfried","is_ca":false},{"name":"Nir Peled","is_ca":false},{"name":"Ali Tafreshi","is_ca":false},{"name":"Sinéad Cuffe","is_ca":false},{"name":"Mary O’ Brien","is_ca":false},{"name":"Suman Rao","is_ca":false},{"name":"Katsuyuki Hotta","is_ca":false},{"name":"Kristel Vandormael","is_ca":false},{"name":"Antonio Riccio","is_ca":false},{"name":"Jing Yang","is_ca":false},{"name":"M. Catherine Pietanza","is_ca":false},{"name":"Julie R. Brahmer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06235330001325926,"gpt":0.4207660967554982,"spread":0.3584127967422389,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009646003,0.0008754477,0.002036453,0.0004345941,0.0002384221,0.0008546412,0.00130913,0.0007249898,0.004287345],"category_scores_gemma":[0.01055482,0.0004464539,0.004777201,0.0004683204,0.000368158,0.000853802,0.0006990473,0.001731911,0.0003474011],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008649815,"about_ca_system_score_gemma":0.0007954619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0011063,"about_ca_topic_score_gemma":0.001819319,"domain_scores_codex":[0.993218,0.004897254,0.0003252117,0.0006953342,0.0006463272,0.0002177701],"domain_scores_gemma":[0.9922998,0.003852878,0.001876436,0.001168685,0.0003958466,0.0004063823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8445023,0.002623045,0.03533982,0.001220603,0.03306606,0.0001811202,0.0001415257,0.007429079,0.005855503,0.000367018,0.004022516,0.06525126],"study_design_scores_gemma":[0.2947522,0.1944775,0.3698161,0.0001885455,0.08654241,0.0007288952,0.000133306,0.02845736,0.0102859,0.001442709,0.01300121,0.0001738866],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836933,0.003008842,0.004575294,0.0002813852,0.0001118135,0.001277187,0.0047897,0.0001382335,0.002124135],"genre_scores_gemma":[0.990405,0.0003995086,0.002402706,0.000357121,0.00009006479,0.0006263761,0.004423589,0.00003564284,0.001260029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009646003,"threshold_uncertainty_score":0.05101353,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2999400187","doi":"10.1200/jco.19.02309","title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1497,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority","funders":"National Cancer Institute","keywords":"Medicine; Guideline; Breast cancer; Oncology; Estrogen receptor; Cancer; Internal medicine; Progesterone receptor; Gynecology; Estrogen; Pathology","authors":[{"name":"Kimberly H. Allison","is_ca":false},{"name":"M. Elizabeth H. Hammond","is_ca":false},{"name":"Mitch Dowsett","is_ca":false},{"name":"Shannon McKernin","is_ca":false},{"name":"Lisa A. Carey","is_ca":false},{"name":"Patrick L. Fitzgibbons","is_ca":false},{"name":"Daniel F. Hayes","is_ca":false},{"name":"Sunil R. Lakhani","is_ca":false},{"name":"Mariana Chávez‐MacGregor","is_ca":false},{"name":"Jane Perlmutter","is_ca":false},{"name":"Charles M. Perou","is_ca":false},{"name":"Meredith M. Regan","is_ca":false},{"name":"David L. Rimm","is_ca":false},{"name":"W. Fraser Symmans","is_ca":false},{"name":"Emina Torlakovic","is_ca":true},{"name":"Leticia Varella","is_ca":false},{"name":"Giuseppe Viale","is_ca":false},{"name":"Tracey Weisberg","is_ca":false},{"name":"Lisa M. McShane","is_ca":false},{"name":"Antonio C. Wolff","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08838685065811515,"gpt":0.424895718177958,"spread":0.3365088675198428,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005878557,0.001208225,0.001992699,0.005505411,0.0008019181,0.002173147,0.003634096,0.004231622,0.005989858],"category_scores_gemma":[0.01975476,0.0005029253,0.002578291,0.004538675,0.0006795712,0.001929853,0.00203543,0.004313238,0.00501659],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003201815,"about_ca_system_score_gemma":0.01000772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01759546,"about_ca_topic_score_gemma":0.0320288,"domain_scores_codex":[0.9945082,0.001826402,0.001200786,0.0002581536,0.001919134,0.0002872404],"domain_scores_gemma":[0.9858483,0.002980091,0.001477386,0.0002970891,0.008734289,0.0006628926],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004604801,0.00008150043,0.001097049,0.006042585,0.0001231712,0.0002355924,0.0001016597,0.0004600888,0.0002104974,0.001671772,0.7166994,0.2732307],"study_design_scores_gemma":[0.0001348951,0.00007181551,0.003678106,0.04238484,0.0004445869,0.001338435,0.0001174411,0.0004495315,0.000209171,0.002858638,0.9482633,0.00004915313],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"methods","genre_scores_codex":[0.003188341,0.6497541,0.008986757,0.2081175,0.01653151,0.00352534,0.0173199,0.001043231,0.09153333],"genre_scores_gemma":[0.01514311,0.765112,0.04252929,0.1031421,0.01051996,0.004566218,0.04287358,0.0003226874,0.01579102],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.01759546,"threshold_uncertainty_score":0.03498608,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2966354200","doi":"10.1200/jco.19.01461","title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1475,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; BC Cancer Agency","funders":"","keywords":"Medicine; Edoxaban; Rivaroxaban; Apixaban; Cancer; Intensive care medicine; Guideline; Randomized controlled trial; Venous thromboembolism; Cochrane Library; Low molecular weight heparin; Ambulatory; Internal medicine; Warfarin; Heparin; Thrombosis","authors":[{"name":"Nigel S. Key","is_ca":false},{"name":"Alok A. Khorana","is_ca":false},{"name":"Nicole M. Kuderer","is_ca":false},{"name":"Kari Bohlke","is_ca":false},{"name":"Agnes Lee","is_ca":true},{"name":"Juan I. Arcelus","is_ca":false},{"name":"Sandra L. Wong","is_ca":false},{"name":"Edward P. Balaban","is_ca":false},{"name":"Christopher R. Flowers","is_ca":false},{"name":"Charles W. Francis","is_ca":false},{"name":"Leigh E. Gates","is_ca":false},{"name":"Ajay K. Kakkar","is_ca":false},{"name":"Mark N. Levine","is_ca":true},{"name":"Howard A. Liebman","is_ca":false},{"name":"Margaret A. Tempero","is_ca":false},{"name":"Gary H. Lyman","is_ca":false},{"name":"Anna Falanga","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1349317751211059,"gpt":0.5122619900840704,"spread":0.3773302149629645,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01322562,0.001466975,0.003694833,0.006255794,0.0009307975,0.002151334,0.003989066,0.005072175,0.004277165],"category_scores_gemma":[0.0424336,0.0008250212,0.005176178,0.006637175,0.0007937102,0.002359881,0.002363513,0.005926387,0.002609626],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004622694,"about_ca_system_score_gemma":0.01825073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02041786,"about_ca_topic_score_gemma":0.03369681,"domain_scores_codex":[0.9878336,0.004361128,0.004078765,0.0004756385,0.002842788,0.000407973],"domain_scores_gemma":[0.9648216,0.010045,0.006694832,0.0006076537,0.01623571,0.001595102],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001417292,0.0001383578,0.002317385,0.05697966,0.001057724,0.0001605081,0.0002944437,0.0006890685,0.0002937525,0.001886487,0.6174792,0.3185617],"study_design_scores_gemma":[0.0006546413,0.0001821671,0.007258233,0.2587397,0.004175917,0.0006581048,0.0003025169,0.0008021105,0.000335504,0.004258504,0.7225043,0.0001284126],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001787518,0.7419116,0.005162652,0.2159622,0.01023174,0.001921192,0.008005239,0.0004413719,0.01457656],"genre_scores_gemma":[0.01111636,0.8327872,0.04690703,0.08124629,0.006037936,0.004073178,0.01369255,0.0001478374,0.003991677],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02041786,"threshold_uncertainty_score":0.06994468,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2141768150","doi":"10.1200/jco.2004.05.063","title":"American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1451,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Disease; Oncology; Guideline; Colorectal cancer; Chemotherapy; Adjuvant therapy; Clinical trial; Cancer; Adjuvant; Adjuvant chemotherapy; Perforation; Intensive care medicine; Surgery; Breast cancer; Pathology","authors":[{"name":"Al B. Benson","is_ca":false},{"name":"Deborah Schrag","is_ca":false},{"name":"Mark R. Somerfield","is_ca":false},{"name":"Alfred M. Cohen","is_ca":false},{"name":"A Figueredo","is_ca":false},{"name":"Patrick J. Flynn","is_ca":false},{"name":"Monika K. Krzyzanowska","is_ca":false},{"name":"Jean A. Maroun","is_ca":false},{"name":"Pamela K. McAllister","is_ca":false},{"name":"Eric Van Cutsem","is_ca":false},{"name":"Melissa Brouwers","is_ca":false},{"name":"Manya Charette","is_ca":false},{"name":"Daniel G. Haller","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.454633654644825,"gpt":0.6437214622989518,"spread":0.1890878076541268,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01368037,0.000922576,0.001590532,0.004908151,0.001581476,0.001421134,0.003919084,0.004834686,0.004656694],"category_scores_gemma":[0.03399431,0.0006668831,0.002795673,0.005244107,0.001408575,0.001078388,0.001639518,0.007465281,0.002711681],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004747853,"about_ca_system_score_gemma":0.02775038,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04228758,"about_ca_topic_score_gemma":0.08138698,"domain_scores_codex":[0.9885513,0.004582847,0.002219385,0.0002986843,0.003790066,0.0005577088],"domain_scores_gemma":[0.9579625,0.008588929,0.006153405,0.0007797007,0.02330663,0.0032088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002614876,0.0001136171,0.005400735,0.004763769,0.0002875669,0.0001872416,0.0001718379,0.0005374743,0.0004864139,0.002567859,0.8742974,0.1109246],"study_design_scores_gemma":[0.0007667042,0.0001917073,0.01962852,0.01619553,0.001069635,0.0006035425,0.0002768481,0.00047703,0.0003716524,0.005281062,0.9550588,0.0000788441],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.006436469,0.2557266,0.01125049,0.5639591,0.039054,0.004796395,0.009497264,0.0005345863,0.1087451],"genre_scores_gemma":[0.06015787,0.3664887,0.1662226,0.307515,0.01727088,0.01289093,0.02443877,0.0003731821,0.04464207],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.04228758,"threshold_uncertainty_score":0.0840829,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974820090","doi":"10.1200/jco.2011.38.0527","title":"Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1420,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Medicine; Karnofsky Performance Status; Lung cancer; Recursive partitioning; Oncology; Internal medicine; Multivariate analysis; Performance status; Brain metastasis; Univariate analysis; Cancer; Univariate; Melanoma; Proportional hazards model; Retrospective cohort study; Metastasis; Multivariate statistics","authors":[{"name":"Paul W. Sperduto","is_ca":false},{"name":"Norbert Kased","is_ca":false},{"name":"David Roberge","is_ca":true},{"name":"Zhiyuan Xu","is_ca":false},{"name":"Ryan Shanley","is_ca":false},{"name":"Xianghua Luo","is_ca":false},{"name":"Penny K. Sneed","is_ca":false},{"name":"Samuel T. Chao","is_ca":false},{"name":"Robert J. Weil","is_ca":false},{"name":"John H. Suh","is_ca":false},{"name":"Amit Bhatt","is_ca":false},{"name":"Ashley W. Jensen","is_ca":false},{"name":"Paul D. Brown","is_ca":false},{"name":"Helen A. Shih","is_ca":false},{"name":"John P. Kirkpatrick","is_ca":false},{"name":"Laurie E. Gaspar","is_ca":false},{"name":"John B. Fiveash","is_ca":false},{"name":"Veronica Chiang","is_ca":false},{"name":"Jonathan Knisely","is_ca":false},{"name":"Christina Maria Sperduto","is_ca":false},{"name":"Nancy U. Lin","is_ca":false},{"name":"Minesh P. Mehta","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2187776587296088,"gpt":0.4748473178935615,"spread":0.2560696591639527,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003652429,0.0009775884,0.0005752731,0.002636471,0.0002185975,0.001403025,0.001025969,0.0007404626,0.007276439],"category_scores_gemma":[0.01353301,0.000240466,0.0005803945,0.001783817,0.0002423664,0.0009866365,0.0006531955,0.0009092136,0.005187707],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007190316,"about_ca_system_score_gemma":0.002086259,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002987627,"about_ca_topic_score_gemma":0.002164079,"domain_scores_codex":[0.9982684,0.000428845,0.0003476382,0.0001438996,0.0007191419,0.000092088],"domain_scores_gemma":[0.9875264,0.002335704,0.001704426,0.0006412888,0.007194224,0.0005979498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.0005039322,0.0001046604,0.03964622,0.001499187,0.0002351374,0.0002446179,0.00005693717,0.00100991,0.001009287,0.0008417796,0.6220488,0.3327996],"study_design_scores_gemma":[0.0002606193,0.000817459,0.1285519,0.002550439,0.0007533989,0.001768448,0.0001477579,0.001960242,0.004633133,0.001145322,0.8573163,0.00009490782],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"dataset","genre_gemma":"empirical","genre_scores_codex":[0.07938715,0.1905333,0.122738,0.07220931,0.05716674,0.004861068,0.3000892,0.005120021,0.1678953],"genre_scores_gemma":[0.3118316,0.1345144,0.09600002,0.01126878,0.03221839,0.005059305,0.3437315,0.001437893,0.06393813],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.007276439,"threshold_uncertainty_score":0.02434212,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2167494200","doi":"10.1200/jco.2014.59.7351","title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1373,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia Hospital","funders":"National Heart, Lung, and Blood Institute; University of North Carolina at Chapel Hill; Wilmot Cancer Institute, University of Rochester Medical Center; Universidad de Granada; McMaster University; School of Medicine, Emory University; Pennsylvania State University; University of Pennsylvania; Penn State Hershey Cancer Institute; University of Rochester; Emory University; Cleveland Clinic; University of Washington; University of Southern California","keywords":"Medicine; Guideline; Cancer; Pulmonary embolism; Deep vein; Intensive care medicine; Randomized controlled trial; Clinical trial; Low molecular weight heparin; Thrombosis; Malignancy; Internal medicine; Surgery","authors":[{"name":"Gary H. Lyman","is_ca":true},{"name":"Kari Bohlke","is_ca":true},{"name":"Alok A. Khorana","is_ca":true},{"name":"Nicole M. Kuderer","is_ca":true},{"name":"Agnes Y. Lee","is_ca":true},{"name":"Juan I. Arcelus","is_ca":true},{"name":"Edward P. Balaban","is_ca":true},{"name":"Jeffrey Clarke","is_ca":true},{"name":"Christopher R. Flowers","is_ca":true},{"name":"Charles W. Francis","is_ca":true},{"name":"Leigh E. Gates","is_ca":true},{"name":"Ajay K. Kakkar","is_ca":true},{"name":"Nigel S. Key","is_ca":true},{"name":"Mark N. Levine","is_ca":true},{"name":"Howard A. Liebman","is_ca":true},{"name":"Margaret A. Tempero","is_ca":true},{"name":"Sandra L. Wong","is_ca":true},{"name":"Mark R. Somerfield","is_ca":true},{"name":"Anna Falanga","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1164542965855454,"gpt":0.4944507079326678,"spread":0.3779964113471224,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008775143,0.001177758,0.003252006,0.006041904,0.0006990636,0.001687145,0.003125943,0.003064065,0.003218373],"category_scores_gemma":[0.03418737,0.0008030801,0.004169662,0.008575381,0.0006593199,0.001832129,0.00169092,0.004133395,0.00175834],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00435903,"about_ca_system_score_gemma":0.01671833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02111933,"about_ca_topic_score_gemma":0.03768582,"domain_scores_codex":[0.9899654,0.003149055,0.003727179,0.00033089,0.002567592,0.0002597849],"domain_scores_gemma":[0.974261,0.006525682,0.006266823,0.0003538008,0.01175154,0.0008411619],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001434452,0.0001286393,0.003574697,0.05813002,0.001052927,0.0001387328,0.0002883828,0.0008052642,0.0003421588,0.001828314,0.5403634,0.3932041],"study_design_scores_gemma":[0.000659827,0.0002062453,0.01377921,0.2202166,0.004712728,0.0008764478,0.0003403709,0.0009920015,0.0005024422,0.004296534,0.7532873,0.0001303459],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.002209967,0.8548603,0.00588873,0.1039537,0.004793731,0.0022815,0.009495793,0.0003497018,0.01616669],"genre_scores_gemma":[0.01138505,0.9005387,0.0391376,0.02569286,0.002447142,0.003785435,0.01356805,0.00009362145,0.003351443],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.02111933,"threshold_uncertainty_score":0.04640794,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2153398041","doi":"10.1200/jco.2009.27.4324","title":"Medulloblastoma Comprises Four Distinct Molecular Variants","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1353,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Deutsche Kinderkrebsstiftung; Pediatric Brain Tumor Foundation; Sontag Foundation; American Brain Tumor Association","keywords":"Medulloblastoma; Medicine; Oncology; Cancer research","authors":[{"name":"Paul A. Northcott","is_ca":true},{"name":"Andrey Korshunov","is_ca":true},{"name":"Hendrik Witt","is_ca":true},{"name":"Thomas Hielscher","is_ca":true},{"name":"Charles G. Eberhart","is_ca":true},{"name":"Stephen C. Mack","is_ca":true},{"name":"Éric Bouffet","is_ca":true},{"name":"Steven C. Clifford","is_ca":true},{"name":"Cynthia Hawkins","is_ca":true},{"name":"Pim J. French","is_ca":true},{"name":"James T. Rutka","is_ca":true},{"name":"Stefan M. Pfister","is_ca":true},{"name":"Michael D. Taylor","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0885155091889863,"gpt":0.4474748075378588,"spread":0.3589592983488725,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000279302,0.0006202239,0.0006096427,0.0009742359,0.0004251372,0.0005909568,0.0003818898,0.0002492213,0.0006197513],"category_scores_gemma":[0.00065085,0.0001844726,0.0004661395,0.0008195743,0.0006217139,0.0002701738,0.0006208947,0.0003839821,0.0002262238],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008710332,"about_ca_system_score_gemma":0.0007073986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006850759,"about_ca_topic_score_gemma":0.008018125,"domain_scores_codex":[0.9996195,0.00003430991,0.00004123068,0.0001428254,0.0001100027,0.00005209333],"domain_scores_gemma":[0.9996418,0.00004569444,0.0001858444,0.00003866655,0.00003288772,0.00005506889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009557731,0.00006262612,0.7636709,0.0001870288,0.0003965268,0.0032092,0.0003107525,0.0007728292,0.1855187,0.001465949,0.0007405058,0.04270936],"study_design_scores_gemma":[0.00005974002,0.0002526154,0.9530003,0.00007084582,0.000347431,0.01667721,0.000369269,0.001229576,0.01955346,0.002293024,0.006122807,0.00002376552],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927924,0.002828538,0.002443175,0.0001737002,0.00001053541,0.0000425267,0.0004390867,0.0001151542,0.001154866],"genre_scores_gemma":[0.9963246,0.0007998132,0.001746434,0.00004959341,0.00001685471,0.00001264924,0.0007223709,0.00002022303,0.0003075508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006850759,"threshold_uncertainty_score":0.01362175,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2107283868","doi":"10.1200/jco.2013.50.3870","title":"Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1290,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Institutes of Health","keywords":"Incidence (geometry); Medicine; Demography; Lung cancer; Cancer; Internal medicine","authors":[{"name":"Anil K. Chaturvedi","is_ca":false},{"name":"William F. Anderson","is_ca":false},{"name":"Joannie Lortet‐Tieulent","is_ca":false},{"name":"María Paula Curado","is_ca":false},{"name":"Jacques Ferlay","is_ca":false},{"name":"Silvia Franceschi","is_ca":false},{"name":"Philip S. Rosenberg","is_ca":false},{"name":"Freddie Bray","is_ca":false},{"name":"Maura L. Gillison","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1488095144977064,"gpt":0.5240838037066335,"spread":0.3752742892089272,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001019944,0.0002775333,0.0003232987,0.002526637,0.0001430576,0.0005992377,0.0003076955,0.0002733683,0.002619344],"category_scores_gemma":[0.002333714,0.0001262123,0.0006323008,0.004273089,0.000123979,0.0004242312,0.0003431232,0.0004239905,0.0007760167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008054909,"about_ca_system_score_gemma":0.0007507524,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02131708,"about_ca_topic_score_gemma":0.01892181,"domain_scores_codex":[0.9993792,0.0001053266,0.0001082603,0.0001607539,0.0001640311,0.00008238915],"domain_scores_gemma":[0.9979571,0.0001729682,0.0009962401,0.0001045503,0.0006684916,0.0001006391],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00004550791,0.00001433078,0.9725296,0.000237542,0.0002360164,0.00005298631,0.0001441918,0.0003520045,0.0002762321,0.0002120704,0.003948666,0.02195087],"study_design_scores_gemma":[0.000006573475,0.00002811054,0.989163,0.00009875604,0.00009962214,0.0002991186,0.0001377837,0.0002933488,0.0001608976,0.00006581508,0.009640804,0.000006248441],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8633998,0.03113473,0.00319896,0.002138568,0.0002064633,0.0001379923,0.08110482,0.0005088059,0.01816994],"genre_scores_gemma":[0.9391891,0.01139136,0.003336699,0.0003560702,0.0001292367,0.0001392943,0.043036,0.00004367105,0.00237862],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02131708,"threshold_uncertainty_score":0.04238605,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2944301866","doi":"10.1200/jco.19.00201","title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1270,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; Ignyta; University of Texas MD Anderson Cancer Center; Genentech","keywords":"Medicine; Clinical endpoint; Radiation therapy; Lung cancer; Randomized controlled trial; Surgery; Systemic therapy; Progression-free survival; Internal medicine; Cancer; Chemotherapy","authors":[{"name":"Daniel R. Gomez","is_ca":false},{"name":"Chad Tang","is_ca":false},{"name":"Jianjun Zhang","is_ca":false},{"name":"George R. Blumenschein","is_ca":false},{"name":"Mike Hernández","is_ca":false},{"name":"Rong Ye","is_ca":false},{"name":"David A. Palma","is_ca":true},{"name":"Alexander V. Louie","is_ca":true},{"name":"D. Ross Camidge","is_ca":false},{"name":"Robert C. Doebele","is_ca":false},{"name":"Ferdinandos Skoulidis","is_ca":false},{"name":"Laurie E. Gaspar","is_ca":false},{"name":"James W. Welsh","is_ca":false},{"name":"Don L. Gibbons","is_ca":false},{"name":"José A. Karam","is_ca":false},{"name":"Brian D. Kavanagh","is_ca":false},{"name":"Anne S. Tsao","is_ca":false},{"name":"Boris Sepesi","is_ca":false},{"name":"Stephen G. Swisher","is_ca":false},{"name":"John V. Heymach","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1064471531521062,"gpt":0.4624029523308717,"spread":0.3559557991787655,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004500488,0.00155279,0.002923273,0.0004794279,0.0004606219,0.001235147,0.001147131,0.001311684,0.002037674],"category_scores_gemma":[0.002721029,0.0005210812,0.002377537,0.0005942282,0.001355979,0.001205909,0.0004932901,0.002949842,0.0004797918],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001068123,"about_ca_system_score_gemma":0.001379631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008749407,"about_ca_topic_score_gemma":0.00245136,"domain_scores_codex":[0.9981008,0.001211933,0.0001298175,0.000244538,0.0001275875,0.0001853549],"domain_scores_gemma":[0.9973368,0.0008134243,0.0007214176,0.0002356232,0.0001450698,0.0007476623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9576256,0.01444351,0.002178422,0.0003547693,0.001252269,0.00003222143,0.00005381904,0.0004728674,0.002293512,0.00004673427,0.000398013,0.02084827],"study_design_scores_gemma":[0.7712145,0.2218151,0.004441426,0.00003041931,0.0009116443,0.00002891295,0.00003081595,0.000615903,0.0004604029,0.00009705166,0.0003380844,0.00001575829],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992716,0.003547471,0.0004274484,0.0003591655,0.0002322025,0.001712013,0.0003264988,0.00004169936,0.0006375611],"genre_scores_gemma":[0.9925727,0.001661584,0.0009754201,0.0006939937,0.0005484186,0.002184655,0.000548207,0.00001319942,0.0008017269],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004500488,"threshold_uncertainty_score":0.02380115,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3032651552","doi":"10.1200/jco.20.00818","title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1242,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Surrey Place Centre; Nova Scotia Cancer Centre; Health Sciences Centre; McGill University Health Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Positive Living North; London Health Sciences Centre","funders":"","keywords":"Medicine; SABR volatility model; Randomized controlled trial; Clinical endpoint; Radiation therapy; Radiosurgery; Prostate cancer; Internal medicine; Ablative case; Oncology; Quality of life (healthcare); Surgery; Cancer","authors":[{"name":"David A. Palma","is_ca":true},{"name":"Robert Olson","is_ca":true},{"name":"Stephen Harrow","is_ca":false},{"name":"Stewart Gaede","is_ca":true},{"name":"Alexander V. Louie","is_ca":true},{"name":"Cornelis J.A. Haasbeek","is_ca":false},{"name":"Liam Mulroy","is_ca":true},{"name":"Michael Lock","is_ca":true},{"name":"George Rodrigues","is_ca":true},{"name":"Brian Yaremko","is_ca":true},{"name":"Devin Schellenberg","is_ca":true},{"name":"Belal Ahmad","is_ca":true},{"name":"Sashendra Senthi","is_ca":false},{"name":"Anand Swaminath","is_ca":true},{"name":"Neil Kopek","is_ca":true},{"name":"Mitchell Liu","is_ca":false},{"name":"Karen Moore","is_ca":false},{"name":"Suzanne Currie","is_ca":false},{"name":"Roel Schlijper","is_ca":true},{"name":"Glenn Bauman","is_ca":true},{"name":"Joanna Laba","is_ca":true},{"name":"Xiaotao Qu","is_ca":true},{"name":"Andrew Warner","is_ca":true},{"name":"Suresh Senan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3547905206584541,"gpt":0.4845785244643184,"spread":0.1297880038058644,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005371226,0.001231181,0.002334806,0.0004455162,0.0005502302,0.001094031,0.0007112121,0.001510032,0.002110485],"category_scores_gemma":[0.003411696,0.0003516152,0.002296807,0.0003887283,0.001270768,0.0009200685,0.0005293405,0.001867223,0.0004324637],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008406406,"about_ca_system_score_gemma":0.001073622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006950105,"about_ca_topic_score_gemma":0.001551281,"domain_scores_codex":[0.9982148,0.001235246,0.00008599028,0.0001608288,0.0001590952,0.0001440353],"domain_scores_gemma":[0.9977702,0.0006177428,0.0005974371,0.0001996123,0.0001455559,0.0006693854],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9579964,0.009828005,0.003211966,0.0006613869,0.001795355,0.00005775486,0.00008352939,0.0008290331,0.002334602,0.0001891718,0.001350394,0.02166238],"study_design_scores_gemma":[0.8885884,0.1031149,0.004772878,0.0000435188,0.0009812134,0.00006430037,0.00002821468,0.0007900657,0.0005251766,0.0002378922,0.0008388257,0.00001459589],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881229,0.004214593,0.0007605388,0.0008676696,0.0003002446,0.003138252,0.0009993553,0.00008630551,0.001510154],"genre_scores_gemma":[0.9891347,0.001671261,0.001242079,0.001275281,0.0004905978,0.003086695,0.001555062,0.00001601209,0.001528269],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005371226,"threshold_uncertainty_score":0.02840608,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2171015116","doi":"10.1200/jco.2009.24.9284","title":"Breast Cancer Subtypes and the Risk of Local and Regional Relapse","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1242,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Medicine; Progesterone receptor; Cytokeratin; Oncology; Internal medicine; Tissue microarray; Immunohistochemistry; Estrogen receptor; Cancer; Epidermal growth factor receptor; Proportional hazards model; Lymph node; Basal (medicine); Mastectomy; Pathology","authors":[{"name":"K. David Voduc","is_ca":true},{"name":"Maggie C.U. Cheang","is_ca":true},{"name":"Scott Tyldesley","is_ca":true},{"name":"Karen Gelmon","is_ca":true},{"name":"Torsten O. Nielsen","is_ca":true},{"name":"Hagen F. Kennecke","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02651815263737387,"gpt":0.3787242963253215,"spread":0.3522061436879476,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003935681,0.0001469399,0.0002539834,0.0002087658,0.0001581298,0.0002201628,0.0002080991,0.0002374634,0.0008017634],"category_scores_gemma":[0.001135733,0.0001147354,0.0003408476,0.0001800859,0.0001485563,0.0001197033,0.0002081919,0.0002846647,0.0001442457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001431766,"about_ca_system_score_gemma":0.0001296111,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007659237,"about_ca_topic_score_gemma":0.001225923,"domain_scores_codex":[0.9997726,0.00005980353,0.00001815365,0.00005885974,0.00004678463,0.00004383455],"domain_scores_gemma":[0.9993379,0.0001138931,0.0003199345,0.00007215636,0.00004803731,0.0001081088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001647213,0.00001566754,0.9964012,0.000005582438,0.00005677717,0.00008857375,0.00001557636,0.000107902,0.000513903,0.000008403202,0.00004573103,0.002576072],"study_design_scores_gemma":[0.000008148849,0.00009848367,0.9980654,0.000003097379,0.00004394203,0.0009845597,0.0000294323,0.0004203751,0.0002137032,0.00001984416,0.0001108026,0.000002299973],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9994963,0.0002403367,0.00008503056,0.00002021377,0.000001269304,0.000002210791,0.0000530112,0.000002887266,0.00009852624],"genre_scores_gemma":[0.9996924,0.00005787557,0.00005367813,0.000007635718,0.000004420593,0.000002245079,0.0001022103,0.000001228204,0.00007829556],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008017634,"threshold_uncertainty_score":0.002682209,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2106869018","doi":"10.1200/jco.2014.55.1192","title":"Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1220,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Watchful waiting; Cancer; Cohort; Hazard ratio; Prostate; Internal medicine; Prostate-specific antigen; Prospective cohort study; Oncology; Cohort study; Gynecology; Confidence interval","authors":[{"name":"Laurence Klotz","is_ca":true},{"name":"Danny Vesprini","is_ca":true},{"name":"Perakaa Sethukavalan","is_ca":true},{"name":"Vibhuti Jethava","is_ca":true},{"name":"Liying Zhang","is_ca":true},{"name":"Suneil Jain","is_ca":true},{"name":"Toshihiro Yamamoto","is_ca":true},{"name":"Alexandre Mamedov","is_ca":true},{"name":"Andrew Loblaw","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03777705958447385,"gpt":0.4154668623716197,"spread":0.3776898027871458,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002557209,0.0004412188,0.000658122,0.0007737243,0.001383646,0.0008571215,0.0004893615,0.0006121111,0.0007478088],"category_scores_gemma":[0.00389412,0.0002981003,0.000689815,0.0006061525,0.0005215876,0.0009398055,0.0009170456,0.0008291917,0.0002710143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004757089,"about_ca_system_score_gemma":0.0006732114,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001545124,"about_ca_topic_score_gemma":0.001981674,"domain_scores_codex":[0.9989234,0.0004310544,0.00009945041,0.000231376,0.0001756267,0.0001391027],"domain_scores_gemma":[0.99632,0.0006178098,0.001116588,0.0005236702,0.0004277624,0.0009941733],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00128965,0.0004532406,0.9922121,0.00001586314,0.0001335235,0.0001844888,0.0001388116,0.00007682428,0.0007502129,0.000009940695,0.0001655849,0.004569732],"study_design_scores_gemma":[0.0002141362,0.003880853,0.9931921,0.00001887192,0.0002113951,0.0009450817,0.0002047099,0.0003927323,0.0003999021,0.00003881318,0.0004831933,0.00001820605],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9992235,0.0002100574,0.0001817531,0.00003581844,0.000008344473,0.00004009157,0.000173882,0.000004762706,0.0001217286],"genre_scores_gemma":[0.9984509,0.00009768277,0.0002159177,0.00004948047,0.00003363088,0.00007420032,0.0009375467,0.00000237792,0.0001381636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002557209,"threshold_uncertainty_score":0.01352394,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2947775394","doi":"10.1200/jco.19.00934","title":"Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1185,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Pembrolizumab; Overall survival; Lung cancer; Safety profile; Phases of clinical research; Survival rate; Cancer; Lung","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.04314214802703654,"gpt":0.41046673368768,"spread":0.3673245856606435,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001846958,0.0004583306,0.0006459915,0.0002604552,0.0002612264,0.0005700823,0.0003765298,0.0005607826,0.0008561437],"category_scores_gemma":[0.00118641,0.0001548807,0.001121918,0.0002659355,0.0002796113,0.0005381521,0.00029578,0.000968816,0.0002022866],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006727204,"about_ca_system_score_gemma":0.00040797,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00060029,"about_ca_topic_score_gemma":0.001252929,"domain_scores_codex":[0.99961,0.0001675237,0.00003226772,0.00007563266,0.00006549234,0.00004900581],"domain_scores_gemma":[0.9991114,0.0001658844,0.0003421814,0.00006538136,0.00006428594,0.0002508247],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1815963,0.007561227,0.6841184,0.0007813181,0.005541081,0.0004598277,0.0003411403,0.003834673,0.009730494,0.0001605794,0.006412074,0.09946293],"study_design_scores_gemma":[0.02610672,0.05308412,0.9097929,0.0001217845,0.00266117,0.0007398803,0.0001253774,0.002311574,0.001623115,0.0001451567,0.00324658,0.00004157398],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956253,0.002592132,0.0002001723,0.0001627139,0.00003254167,0.00005949845,0.0008404686,0.00001334101,0.0004737913],"genre_scores_gemma":[0.9961199,0.0007111621,0.0001275062,0.0002237841,0.00005705197,0.00005939916,0.002417395,0.000004097214,0.0002798524],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001846958,"threshold_uncertainty_score":0.009767771,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149568734","doi":"10.1200/jco.2006.08.2024","title":"Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1172,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Alberta; University of Ottawa; University of British Columbia","funders":"","keywords":"Medicine; Aerobic exercise; Breast cancer; Quality of life (healthcare); Physical therapy; Randomized controlled trial; Internal medicine; Psychosocial; Lymphedema; Cancer; Lean body mass; Nursing","authors":[{"name":"Kerry S. Courneya","is_ca":true},{"name":"Roanne Segal","is_ca":true},{"name":"John R. Mackey","is_ca":true},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Robert D. Reid","is_ca":true},{"name":"Christine M. Friedenreich","is_ca":true},{"name":"Aliya B. Ladha","is_ca":true},{"name":"Caroline Proulx","is_ca":true},{"name":"Jeffrey K. Vallance","is_ca":true},{"name":"Kirstin N. Lane","is_ca":true},{"name":"Yutaka Yasui","is_ca":true},{"name":"Donald C. McKenzie","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01823382411926726,"gpt":0.3822727521623391,"spread":0.3640389280430718,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003577485,0.001154889,0.003239824,0.0005257136,0.0008104252,0.001118178,0.001012553,0.002240641,0.004641956],"category_scores_gemma":[0.006304427,0.0006497242,0.002631629,0.0007785644,0.001074453,0.0007829343,0.0004172995,0.002205412,0.0004042612],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001385992,"about_ca_system_score_gemma":0.002994745,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004938067,"about_ca_topic_score_gemma":0.009597859,"domain_scores_codex":[0.997549,0.001586949,0.000219661,0.0003039784,0.0001528922,0.0001875364],"domain_scores_gemma":[0.9965449,0.001166801,0.00106093,0.0002080125,0.000302372,0.0007169506],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9831536,0.003799866,0.001082976,0.0009209297,0.001997801,0.00002411905,0.00003225618,0.0001681792,0.0004359105,0.00004474924,0.0004249839,0.007914527],"study_design_scores_gemma":[0.9811532,0.01618447,0.001255811,0.00006379755,0.0008475623,0.00001067401,0.00001162398,0.000176606,0.00006951899,0.0000291034,0.0001917849,0.000005926784],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9698275,0.01584221,0.0006834571,0.001639876,0.0009064003,0.008581127,0.0009812429,0.0001119486,0.001426348],"genre_scores_gemma":[0.9756883,0.005338641,0.002424357,0.001527203,0.0007743636,0.01206948,0.0007276179,0.0000161308,0.001433714],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004938067,"threshold_uncertainty_score":0.01891977,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2147013683","doi":"10.1200/jco.2012.43.2674","title":"Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1163,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; McGill University","funders":"National Cancer Institute","keywords":"Medicine; Procarbazine; Lomustine; Internal medicine; Hazard ratio; Oligodendroglial Tumor; Vincristine; Oligodendroglioma; Gastroenterology; Chemoradiotherapy; Radiation therapy; Proportional hazards model; Nuclear medicine; Oncology; Chemotherapy; Glioma; Confidence interval; Astrocytoma","authors":[{"name":"Gregory Cairncross","is_ca":true},{"name":"Meihua Wang","is_ca":true},{"name":"Edward Shaw","is_ca":true},{"name":"Robert B. Jenkins","is_ca":true},{"name":"David Brachman","is_ca":true},{"name":"Jan C. Buckner","is_ca":true},{"name":"Karen Fink","is_ca":true},{"name":"Luís Souhami","is_ca":true},{"name":"Normand Laperrière","is_ca":true},{"name":"Walter Curran","is_ca":true},{"name":"Minesh P. Mehta","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.146231725299461,"gpt":0.5003239368345028,"spread":0.3540922115350418,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001407038,0.001336559,0.001688129,0.0003585402,0.0004371064,0.001145863,0.001274059,0.0012361,0.007180243],"category_scores_gemma":[0.001015848,0.0004950636,0.00125742,0.0004216529,0.0006225028,0.0005992034,0.0003416041,0.002846482,0.001598767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009583677,"about_ca_system_score_gemma":0.001416106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001428587,"about_ca_topic_score_gemma":0.003367736,"domain_scores_codex":[0.9995558,0.0002652035,0.00001792368,0.00005635045,0.00003397403,0.00007088309],"domain_scores_gemma":[0.9993888,0.0001483289,0.0001402539,0.00005152798,0.00003355683,0.0002375419],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8784093,0.01739303,0.003042949,0.0008660844,0.002007558,0.0001346481,0.0001197201,0.00199414,0.01041437,0.0003335089,0.006707652,0.0785771],"study_design_scores_gemma":[0.8452702,0.1437452,0.005022413,0.0000562556,0.0006586037,0.0001736904,0.0000378316,0.0008153133,0.00103922,0.0001489317,0.00301032,0.00002196217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858074,0.0055626,0.0006776947,0.0008902107,0.0002563039,0.001670222,0.001978375,0.0002134131,0.002943814],"genre_scores_gemma":[0.9761088,0.003752497,0.002069364,0.001454302,0.0002753429,0.003944638,0.003749439,0.0000547076,0.008590916],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007180243,"threshold_uncertainty_score":0.02402031,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3009099064","doi":"10.1200/jco.19.03136","title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1154,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Internal medicine; Hazard ratio; Placebo; Oncology; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Surgery; Cancer; Progressive disease; Chemotherapy; Confidence interval; Pathology; Immunotherapy; Cisplatin","authors":[{"name":"Shirish M. Gadgeel","is_ca":false},{"name":"Delvys Rodríguez‐Abreu","is_ca":false},{"name":"Giovanna Speranza","is_ca":true},{"name":"Emilio Esteban","is_ca":false},{"name":"Enriqueta Felip","is_ca":false},{"name":"Manuel Dómine","is_ca":false},{"name":"Rina Hui","is_ca":false},{"name":"Maximilian J. Hochmair","is_ca":false},{"name":"Philip R. Clingan","is_ca":false},{"name":"Steven Powell","is_ca":false},{"name":"Susanna Y. Cheng","is_ca":true},{"name":"Helge Bischoff","is_ca":false},{"name":"Nir Peled","is_ca":false},{"name":"Francesco Grossi","is_ca":false},{"name":"Ross Jennens","is_ca":false},{"name":"Martin Reck","is_ca":false},{"name":"Edward B. Garon","is_ca":false},{"name":"Silvia Novello","is_ca":false},{"name":"Belén Rubio‐Viqueira","is_ca":false},{"name":"Michael Boyer","is_ca":false},{"name":"Takayasu Kurata","is_ca":false},{"name":"Jhanelle E. Gray","is_ca":false},{"name":"Jing Yang","is_ca":false},{"name":"Tuba Öcek Baş","is_ca":false},{"name":"M. Catherine Pietanza","is_ca":false},{"name":"Marina Chiara Garassino","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1020767828221736,"gpt":0.432874076965801,"spread":0.3307972941436275,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008134195,0.001317069,0.003929759,0.001221455,0.0003247976,0.001617596,0.001335328,0.001037736,0.0117489],"category_scores_gemma":[0.01195274,0.000723857,0.009599088,0.001685517,0.00025417,0.001295991,0.001107672,0.002274224,0.001410549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001600803,"about_ca_system_score_gemma":0.001672184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003240621,"about_ca_topic_score_gemma":0.007268632,"domain_scores_codex":[0.9939179,0.003290142,0.0005954698,0.000743755,0.001142197,0.000310468],"domain_scores_gemma":[0.9936399,0.002488716,0.001848956,0.0007784866,0.0009074987,0.0003365757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7076643,0.001220295,0.01609198,0.01506324,0.1020061,0.0002587469,0.0001324178,0.003465297,0.005128681,0.000762166,0.06820032,0.08000656],"study_design_scores_gemma":[0.3827682,0.03799922,0.1781381,0.002903207,0.2766388,0.0009868219,0.0001556096,0.003382353,0.003978368,0.001327628,0.1114632,0.000258497],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5188974,0.1184525,0.008549722,0.004001757,0.003784005,0.01472206,0.2948784,0.001172984,0.03554117],"genre_scores_gemma":[0.8139512,0.01648247,0.007222956,0.006304524,0.001341772,0.006087393,0.1366208,0.0004757408,0.01151323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0117489,"threshold_uncertainty_score":0.04301828,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2147058464","doi":"10.1200/jco.2004.04.188","title":"Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1146,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Prophylactic Mastectomy; Breast cancer; Prophylactic Surgery; Mastectomy; Oophorectomy; Cancer; BRCA mutation; Gynecology; Surgery; Germline mutation; Ovarian cancer; Oncology; Internal medicine; Hysterectomy; Mutation","authors":[{"name":"Timothy R. Rebbeck","is_ca":true},{"name":"Tara M. Friebel","is_ca":true},{"name":"Henry T. Lynch","is_ca":true},{"name":"Susan L. Neuhausen","is_ca":true},{"name":"Laura van ‘t Veer","is_ca":true},{"name":"Judy E. Garber","is_ca":true},{"name":"D. Gareth Evans","is_ca":true},{"name":"Steven A. Narod","is_ca":true},{"name":"Claudine Isaacs","is_ca":true},{"name":"Ellen Matloff","is_ca":true},{"name":"Mary B. Daly","is_ca":true},{"name":"Olufunmilayo I. Olopade","is_ca":true},{"name":"Barbara Weber","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03248792481459869,"gpt":0.3905868678752462,"spread":0.3580989430606475,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009555329,0.0003355895,0.0004259124,0.0002537429,0.0001272474,0.0001954599,0.0001400576,0.0002337326,0.00083395],"category_scores_gemma":[0.001440282,0.0001404282,0.0003280506,0.000157784,0.000227849,0.0001731334,0.0002025923,0.0002211339,0.00005756529],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001041474,"about_ca_system_score_gemma":0.0001686167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000537993,"about_ca_topic_score_gemma":0.0007724811,"domain_scores_codex":[0.999741,0.0001283542,0.00001292121,0.00004290656,0.00005309107,0.00002180562],"domain_scores_gemma":[0.9994949,0.0001473094,0.0002250386,0.00004335907,0.00002343754,0.00006588665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03162432,0.0006132154,0.9092895,0.0001959466,0.001527577,0.0003801078,0.0001108916,0.0005435529,0.004336532,0.00009187031,0.000434974,0.05085141],"study_design_scores_gemma":[0.001910063,0.008922986,0.9849948,0.00002849493,0.000705913,0.001093779,0.00006358864,0.0007823285,0.0008225603,0.0001147238,0.000551816,0.000008963514],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983925,0.001201074,0.00008855175,0.00005114606,0.000005866724,0.00001012487,0.00006961525,0.00000381881,0.0001773617],"genre_scores_gemma":[0.9992613,0.0003859668,0.00009789192,0.00002216411,0.00001313381,0.000006432279,0.00009627366,7.244973e-7,0.0001161452],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009555329,"threshold_uncertainty_score":0.005053401,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165542862","doi":"10.1200/jco.2007.12.4008","title":"Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1145,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prednisone; Prostate cancer; Internal medicine; Urology; Survival analysis; Surgery; Oncology; Cancer; Chemotherapy","authors":[{"name":"Dominik Berthold","is_ca":true},{"name":"Gregory R. Pond","is_ca":true},{"name":"Freidele Soban","is_ca":true},{"name":"Ronald de Wit","is_ca":true},{"name":"Mario A. Eisenberger","is_ca":true},{"name":"Ian F. Tannock","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2067678927162186,"gpt":0.5167604900016837,"spread":0.309992597285465,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001596309,0.0003309885,0.0008848904,0.0003066389,0.0001412442,0.00063684,0.0003443819,0.0004357151,0.0009492767],"category_scores_gemma":[0.001710771,0.0001878866,0.001219806,0.0007174549,0.0001729214,0.0003587765,0.0002962849,0.0007921121,0.0001575983],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004598443,"about_ca_system_score_gemma":0.0005516752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00294679,"about_ca_topic_score_gemma":0.00519901,"domain_scores_codex":[0.9994414,0.0002880641,0.00004804453,0.00006997775,0.0001059519,0.00004662599],"domain_scores_gemma":[0.9989476,0.0002431034,0.0004732612,0.00007660328,0.00007201463,0.0001874148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2844628,0.001777895,0.484172,0.003353107,0.01776068,0.0004637138,0.0002444642,0.004271169,0.002794165,0.0005919756,0.01250646,0.1876015],"study_design_scores_gemma":[0.1079717,0.02417064,0.8100618,0.00101837,0.03121755,0.000971271,0.0001649723,0.00261889,0.0009833754,0.0008896638,0.01985641,0.00007548912],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9634271,0.02952726,0.0002981708,0.000661297,0.0001380043,0.0002055989,0.003966817,0.00002267072,0.001753071],"genre_scores_gemma":[0.9820808,0.01167107,0.0003183231,0.0005455959,0.0002240272,0.0001418535,0.004268914,0.000007878692,0.0007414133],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00294679,"threshold_uncertainty_score":0.008442163,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2141604895","doi":"10.1200/jco.2014.57.2909","title":"Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1137,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Hippocampal formation; Compartment (ship); Whole brain radiotherapy; Radiation therapy; Neural stem cell; Internal medicine; Stem cell; Brain metastasis; Cancer; Metastasis; Biology","authors":[{"name":"Vinai Gondi","is_ca":false},{"name":"Stephanie L. Pugh","is_ca":false},{"name":"Wolfgang A. Tomé","is_ca":false},{"name":"Chip Caine","is_ca":false},{"name":"B. Corn","is_ca":false},{"name":"Andrew A. Kanner","is_ca":false},{"name":"Howard A. Rowley","is_ca":false},{"name":"Vijayananda Kundapur","is_ca":true},{"name":"Albert S. DeNittis","is_ca":false},{"name":"Jeffrey Greenspoon","is_ca":true},{"name":"André Konski","is_ca":false},{"name":"Glenn Bauman","is_ca":false},{"name":"Sunjay Shah","is_ca":false},{"name":"Wenyin Shi","is_ca":false},{"name":"Merideth M Wendland","is_ca":false},{"name":"Lisa A. Kachnic","is_ca":false},{"name":"Minesh P. Mehta","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1231112028158909,"gpt":0.4379247600735918,"spread":0.3148135572577009,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001597615,0.001374455,0.001227776,0.0003370588,0.0004335057,0.000704998,0.0007722942,0.0008979278,0.0017541],"category_scores_gemma":[0.000835489,0.0003787809,0.001517951,0.0005418962,0.0008207103,0.0005173881,0.0002840512,0.001939655,0.0004127228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007061627,"about_ca_system_score_gemma":0.001633667,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001383554,"about_ca_topic_score_gemma":0.002452692,"domain_scores_codex":[0.9996057,0.000217252,0.00002622495,0.00005610713,0.00003278082,0.00006201657],"domain_scores_gemma":[0.9995165,0.00008275059,0.0001738066,0.00007044463,0.00002791404,0.0001286544],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8604203,0.04360201,0.01192558,0.0008513583,0.001812137,0.0001516865,0.0002989486,0.002035246,0.01584447,0.0002139586,0.001343865,0.06150036],"study_design_scores_gemma":[0.5365881,0.4447986,0.01331911,0.00004651228,0.0006491979,0.0001893649,0.00004810885,0.0008724002,0.002576557,0.0001265404,0.0007584234,0.00002717896],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975883,0.0005576541,0.0002208972,0.00009277002,0.00002659501,0.0009995374,0.0002308853,0.00002550215,0.0002578425],"genre_scores_gemma":[0.9952159,0.0009180121,0.0007770483,0.0002683543,0.00007837005,0.001836974,0.0004516018,0.00001044746,0.0004431824],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0017541,"threshold_uncertainty_score":0.008449078,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3154805493","doi":"10.1200/jco.21.00174","title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1109,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Chemotherapy; Lung cancer; Hazard ratio; Oncology; Clinical endpoint; Cancer; Surgery; Randomized controlled trial; Immunotherapy; Confidence interval","authors":[{"name":"Martin Reck","is_ca":false},{"name":"Delvys Rodríguez‐Abreu","is_ca":false},{"name":"Andrew Robinson","is_ca":true},{"name":"Rina Hui","is_ca":false},{"name":"Tibor Csőszi","is_ca":false},{"name":"Andrea Fülöp","is_ca":false},{"name":"Maya Gottfried","is_ca":false},{"name":"Nir Peled","is_ca":false},{"name":"Ali Tafreshi","is_ca":false},{"name":"Sinéad Cuffe","is_ca":false},{"name":"Mary O’Brien","is_ca":false},{"name":"Suman Rao","is_ca":false},{"name":"Katsuyuki Hotta","is_ca":false},{"name":"Ticiana Leal","is_ca":false},{"name":"Jonathan W. Riess","is_ca":false},{"name":"Erin Jensen","is_ca":false},{"name":"Bin Zhao","is_ca":false},{"name":"M. Catherine Pietanza","is_ca":false},{"name":"Julie R. Brahmer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08258638092140791,"gpt":0.4375760962292222,"spread":0.3549897153078143,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001846955,0.0004969647,0.001412948,0.0003842457,0.0003533933,0.0005990709,0.0003442767,0.0007107889,0.002062466],"category_scores_gemma":[0.001936759,0.0001967322,0.002195633,0.0002326491,0.0004017418,0.0006987596,0.0003736959,0.001401366,0.000330324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008711096,"about_ca_system_score_gemma":0.0005737061,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006595688,"about_ca_topic_score_gemma":0.00152016,"domain_scores_codex":[0.9991887,0.0003736842,0.00006626579,0.0001230705,0.0001044001,0.0001439037],"domain_scores_gemma":[0.9989121,0.0002025301,0.0003978526,0.00006813586,0.00005001945,0.0003693693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8258236,0.01469319,0.03912129,0.0006016319,0.004227155,0.000127918,0.0001185953,0.003025883,0.004469945,0.0001863885,0.002497188,0.1051072],"study_design_scores_gemma":[0.1441044,0.596019,0.2431728,0.0001933869,0.00425897,0.000306455,0.0001206775,0.004597287,0.003074841,0.0005954417,0.003498005,0.00005882498],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936898,0.003959774,0.0002972933,0.0002737335,0.0001620917,0.0002517071,0.0004804268,0.00001740035,0.0008678136],"genre_scores_gemma":[0.9973447,0.0006520136,0.0001673869,0.0002540896,0.0001268334,0.0002435262,0.0006575474,0.000003220557,0.0005507508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002062466,"threshold_uncertainty_score":0.009767771,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3217126890","doi":"10.1200/jco.21.02229","title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1104,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation","funders":"National Cancer Institute; EMD Serono; Genentech; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Amgen; Celldex Therapeutics; Array BioPharma; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Melanoma; Metastatic melanoma; Clinical trial; Immunotherapy","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.07445865462662754,"gpt":0.4172274161971886,"spread":0.342768761570561,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001462872,0.000381012,0.0008786551,0.0002106879,0.0003149183,0.0004977289,0.0002934766,0.0005482822,0.001411486],"category_scores_gemma":[0.001050559,0.0001360988,0.001240785,0.0001660326,0.0003389964,0.0004732285,0.000250312,0.00129132,0.0002759342],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004839983,"about_ca_system_score_gemma":0.0004190403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000286169,"about_ca_topic_score_gemma":0.000793509,"domain_scores_codex":[0.9996543,0.0001426728,0.00002760111,0.00005726587,0.00004760197,0.0000706005],"domain_scores_gemma":[0.9991964,0.0001530339,0.0002247227,0.00004255068,0.0000404538,0.0003428046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6926301,0.01176916,0.1147434,0.0007893926,0.003857503,0.0004063276,0.0001950602,0.004567482,0.01463116,0.0001937631,0.003693044,0.1525237],"study_design_scores_gemma":[0.09144557,0.5618232,0.3283553,0.0002396356,0.003633594,0.000856765,0.0001438702,0.004232776,0.004309725,0.0006152577,0.004278771,0.00006559282],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948619,0.003873247,0.000144743,0.0002280234,0.00008948347,0.00006284539,0.0002203649,0.000009747335,0.0005094923],"genre_scores_gemma":[0.9978955,0.00065086,0.0001144421,0.0002508629,0.0001460591,0.00007198717,0.0004267212,0.000002150719,0.0004414348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001462872,"threshold_uncertainty_score":0.007736504,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2129931005","doi":"10.1200/jco.2007.13.4452","title":"Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1077,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Medicine; Imatinib mesylate; Imatinib; GiST; Regimen; Internal medicine; Surgery; Oncology; Phases of clinical research; Clinical trial; Gastroenterology; Tyrosine-kinase inhibitor; Progression-free survival; Chemotherapy; Stromal cell; Cancer","authors":[{"name":"Charles D. Blanke","is_ca":false},{"name":"Cathryn Rankin","is_ca":false},{"name":"George D. Demetri","is_ca":false},{"name":"Christopher W. Ryan","is_ca":false},{"name":"Margaret von Mehren","is_ca":false},{"name":"Robert S. Benjamin","is_ca":false},{"name":"A. Kevin Raymond","is_ca":false},{"name":"Vivien Bramwell","is_ca":false},{"name":"Laurence H. Baker","is_ca":false},{"name":"Robert G. Maki","is_ca":false},{"name":"Michael Tanaka","is_ca":false},{"name":"J. Randolph Hecht","is_ca":false},{"name":"Michael C. Heinrich","is_ca":false},{"name":"Christopher D.�M. Fletcher","is_ca":false},{"name":"John J. Crowley","is_ca":false},{"name":"Ernest C. Borden","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1692056531082675,"gpt":0.4733452979920085,"spread":0.304139644883741,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001663125,0.001588627,0.002024617,0.0004112576,0.0004353848,0.001094348,0.0008188554,0.00158542,0.005802337],"category_scores_gemma":[0.001646822,0.0004814245,0.001316958,0.0004943925,0.001214101,0.0008656766,0.0004173792,0.002877357,0.0008477087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009948981,"about_ca_system_score_gemma":0.002166566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001577708,"about_ca_topic_score_gemma":0.00424394,"domain_scores_codex":[0.9993035,0.0004308832,0.00003280364,0.00008147726,0.0000507363,0.0001006914],"domain_scores_gemma":[0.998753,0.0003203033,0.0002725941,0.00006946626,0.00005994331,0.0005246942],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9713538,0.01093209,0.001323562,0.0001715381,0.0004393465,0.00004502247,0.00006256959,0.0004426657,0.003791663,0.00009857586,0.0009772053,0.01036191],"study_design_scores_gemma":[0.9426228,0.05468228,0.001485869,0.000009147942,0.0001313398,0.00002149878,0.00001677443,0.0003593803,0.0003296468,0.00008108497,0.0002516846,0.00000846634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939905,0.0009038607,0.0004249306,0.0005913379,0.0001954331,0.002017138,0.0007065029,0.00007769102,0.00109258],"genre_scores_gemma":[0.9890941,0.0009008057,0.001514836,0.001237034,0.0002586736,0.003623623,0.001456442,0.00002568088,0.001888801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005802337,"threshold_uncertainty_score":0.01941073,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157996158","doi":"10.1200/jco.2009.24.2180","title":"Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1069,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Watchful waiting; Prostate cancer; Hazard ratio; Cohort; Cancer; Prostate-specific antigen; Internal medicine; Prostate; Prospective cohort study; Proportional hazards model; Cohort study; Oncology; Gynecology; Surgery; Confidence interval","authors":[{"name":"Laurence Klotz","is_ca":true},{"name":"Liying Zhang","is_ca":true},{"name":"Adam Lam","is_ca":true},{"name":"Robert K. Nam","is_ca":true},{"name":"Alexandre Mamedov","is_ca":true},{"name":"Andrew Loblaw","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06908816564333845,"gpt":0.4725403227283844,"spread":0.403452157085046,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001901303,0.0003820278,0.0004895861,0.0005457305,0.0005774111,0.0007590081,0.0003081191,0.0005127308,0.0006790248],"category_scores_gemma":[0.004808395,0.0001981887,0.0005064964,0.0003512506,0.0003942953,0.0005852392,0.0005244186,0.0005476763,0.0001915191],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003672435,"about_ca_system_score_gemma":0.0003753384,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001446021,"about_ca_topic_score_gemma":0.001543769,"domain_scores_codex":[0.9992049,0.0003458477,0.0000576597,0.0001742174,0.0001100389,0.0001073384],"domain_scores_gemma":[0.9964646,0.0007808866,0.001214572,0.0002807208,0.0003269008,0.0009322915],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009954799,0.0001720256,0.9956956,0.000009433354,0.00007581869,0.0001232617,0.0000723745,0.00006131084,0.0003470377,0.000006467171,0.00007027587,0.002370914],"study_design_scores_gemma":[0.00008492207,0.002166429,0.9963636,0.000006713485,0.00009347961,0.0005502701,0.0001086571,0.0003068632,0.0001373958,0.00001902239,0.0001540072,0.000008593035],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9995149,0.0001981747,0.00006657365,0.00001795946,0.000004343727,0.00001040734,0.00009552219,0.000002457323,0.00008973316],"genre_scores_gemma":[0.9995328,0.0000375685,0.00004290654,0.00001573916,0.00001432064,0.00001162569,0.0002825838,0.000001086589,0.00006133191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001901303,"threshold_uncertainty_score":0.01005512,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137383164","doi":"10.1200/jco.2007.14.6217","title":"Cancer Survivors’ Adherence to Lifestyle Behavior Recommendations and Associations With Health-Related Quality of Life: Results From the American Cancer Society's SCS-II","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1025,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Dalhousie University","funders":"","keywords":"Medicine; Psychological intervention; Quality of life (healthcare); Cancer; Gerontology; Cancer survivor; Demography; Internal medicine; Psychiatry","authors":[{"name":"Christopher M. Blanchard","is_ca":true},{"name":"Kerry S. Courneya","is_ca":true},{"name":"Kevin Stein","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.24266289197625,"gpt":0.5096895033310943,"spread":0.2670266113548443,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011192,0.0002332321,0.0002986811,0.001291128,0.0002836534,0.0004645647,0.0003115676,0.0004879862,0.001904017],"category_scores_gemma":[0.004028428,0.000140718,0.0006605224,0.001665381,0.0001837832,0.0002567956,0.0005826459,0.0003812358,0.0003981428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003954941,"about_ca_system_score_gemma":0.000540677,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02850829,"about_ca_topic_score_gemma":0.03520096,"domain_scores_codex":[0.999505,0.000102378,0.00007756762,0.00006339682,0.0001941755,0.00005738601],"domain_scores_gemma":[0.9966983,0.0006546209,0.0009833716,0.0001880383,0.001024326,0.0004514772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00006141272,0.00003728029,0.9973339,0.00001949098,0.00006536228,0.00000549771,0.00004732781,0.00005750268,0.00003537573,0.000002501953,0.0003900969,0.00194432],"study_design_scores_gemma":[0.000006238407,0.0000462237,0.9995199,0.000006711299,0.00002514047,0.00001470171,0.00007720258,0.00006032681,0.00002234556,0.000002127466,0.0002170445,0.000001937235],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924793,0.0003400458,0.00008692253,0.0001428624,0.00001321448,0.00005291919,0.005506296,0.00001816591,0.001360286],"genre_scores_gemma":[0.9918642,0.0002588413,0.0001129192,0.00007377215,0.00001518687,0.00007085045,0.007071595,0.000005944201,0.0005267421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02850829,"threshold_uncertainty_score":0.05668467,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125885282","doi":"10.1200/jco.2014.58.1967","title":"Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1023,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Medicine; Carboplatin; Chemotherapy; Oncology; Human Epidermal Growth Factor Receptor 2; Triple-negative breast cancer; Internal medicine; Triple negative; Breast cancer; Cancer research; Epidermal growth factor receptor; Receptor; Pathology; Cancer; Cisplatin","authors":[{"name":"Carsten Denkert","is_ca":false},{"name":"Gϋnter von Minckwitz","is_ca":false},{"name":"Jan C. Brase","is_ca":false},{"name":"Bruno V. Sinn","is_ca":false},{"name":"Stephan Gade","is_ca":false},{"name":"Ralf Kronenwett","is_ca":false},{"name":"Berit M. Pfitzner","is_ca":false},{"name":"Christoph Salat","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Wolfgang Schmitt","is_ca":false},{"name":"Christian Schem","is_ca":false},{"name":"Karin Fisch","is_ca":false},{"name":"Silvia Darb‐Esfahani","is_ca":false},{"name":"Keyur Mehta","is_ca":false},{"name":"Christos Sotiriou","is_ca":false},{"name":"Stephan Wienert","is_ca":false},{"name":"Peter Klare","is_ca":false},{"name":"Fabrice André","is_ca":false},{"name":"Frederick Klauschen","is_ca":false},{"name":"Jens‐Uwe Blohmer","is_ca":false},{"name":"Kristin Krappmann","is_ca":false},{"name":"Marcus Schmidt","is_ca":false},{"name":"Hans Tesch","is_ca":false},{"name":"Sherko Kümmel","is_ca":false},{"name":"Hans‐Peter Sinn","is_ca":false},{"name":"Christian Jackisch","is_ca":true},{"name":"Manfred Dietel","is_ca":false},{"name":"Toralf Reimer","is_ca":false},{"name":"Michael Untch","is_ca":false},{"name":"Sibylle Loibl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03804349880468626,"gpt":0.3858530708677692,"spread":0.3478095720630829,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005642175,0.0001869442,0.0002922773,0.000135617,0.00007829665,0.0002086665,0.0001345479,0.0002476552,0.0007462537],"category_scores_gemma":[0.0008024811,0.0001250049,0.0002286331,0.0001399683,0.0001746574,0.0001679547,0.000131655,0.0003564007,0.0001107052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000313297,"about_ca_system_score_gemma":0.0002363144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003227382,"about_ca_topic_score_gemma":0.0007626133,"domain_scores_codex":[0.9998038,0.00008273902,0.0000170336,0.00003497732,0.0000348374,0.00002657685],"domain_scores_gemma":[0.9995852,0.0001505066,0.0001060019,0.00002666037,0.00002185295,0.0001097256],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09529666,0.002303106,0.8039027,0.0002482571,0.0004746833,0.0002460254,0.0001707295,0.001455593,0.04463955,0.00004978955,0.0005680839,0.05064472],"study_design_scores_gemma":[0.001458774,0.01524502,0.9760985,0.00002126843,0.0002355824,0.0004841918,0.00008002685,0.001363792,0.003982644,0.00004831899,0.0009747104,0.000007173392],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9995087,0.0002563876,0.00002522566,0.00001815109,0.000003666389,0.00001164549,0.00003767028,0.000002184533,0.0001362583],"genre_scores_gemma":[0.9995537,0.00007374492,0.00005208364,0.00002550925,0.000008084136,0.00002064311,0.0001311001,8.256291e-7,0.0001342435],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007462537,"threshold_uncertainty_score":0.002983928,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2130244150","doi":"10.1200/jco.2005.08.391","title":"Dignity Therapy: A Novel Psychotherapeutic Intervention for Patients Near the End of Life","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":1020,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Manitoba; CancerCare Manitoba; St. Boniface Hospital","funders":"","keywords":"Dignity; Medicine; Intervention (counseling); Psychosocial; Feeling; Distress; Palliative care; Meaning (existential); Psychotherapist; Depression (economics); Psychiatry; Nursing; Clinical psychology; Psychology; Social psychology","authors":[{"name":"Harvey Max Chochinov","is_ca":true},{"name":"Thomas F. Hack","is_ca":true},{"name":"Thomas Hassard","is_ca":true},{"name":"Linda J. Kristjanson","is_ca":true},{"name":"Susan McClement","is_ca":true},{"name":"Mike Harlos","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3032002047393502,"gpt":0.5107964315329052,"spread":0.207596226793555,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002669992,0.0001517311,0.0001233251,0.0001133347,0.0004110138,0.0002286289,0.0002191328,0.0003312793,0.002266148],"category_scores_gemma":[0.0006004677,0.00004421191,0.000189931,0.00006472415,0.0003462906,0.0003461925,0.0008494225,0.0004472623,0.0001207793],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002279837,"about_ca_system_score_gemma":0.0005455787,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002251438,"about_ca_topic_score_gemma":0.00117419,"domain_scores_codex":[0.9999075,0.00004755281,0.000004522195,0.000009841963,0.00001501722,0.00001559007],"domain_scores_gemma":[0.9998757,0.00004535888,0.00001846929,0.000003960505,0.000005309972,0.00005111342],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.003533298,0.009849054,0.01694628,0.002906969,0.0001017547,0.002615773,0.01799473,0.0005791396,0.02406598,0.002357417,0.0050431,0.9140066],"study_design_scores_gemma":[0.01671309,0.1159269,0.3105972,0.005915757,0.0008238005,0.03298862,0.04853579,0.006453245,0.03835341,0.01109792,0.4123418,0.000252392],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764197,0.004667348,0.003738942,0.002279961,0.0002710562,0.000474008,0.00002980906,0.00005916661,0.01205999],"genre_scores_gemma":[0.9849183,0.002748037,0.008205679,0.0009037639,0.00007632795,0.0004531809,0.00003586574,0.000005223819,0.002653602],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002266148,"threshold_uncertainty_score":0.007580996,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121708973","doi":"10.1200/jco.2004.09.059","title":"Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1015,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Stage (stratigraphy); Adjuvant therapy; Internal medicine; Proportional hazards model; Colorectal cancer; Levamisole; Multivariate analysis; Oncology; Adjuvant; Survival analysis; Cancer; Radiation therapy; Surgery","authors":[{"name":"Sharlene Gill","is_ca":true},{"name":"Charles L. Loprinzi","is_ca":true},{"name":"Daniel J. Sargent","is_ca":true},{"name":"Stephan D. Thomé","is_ca":true},{"name":"Steven R. Alberts","is_ca":true},{"name":"Daniel G. Haller","is_ca":true},{"name":"Jacqueline Benedetti","is_ca":true},{"name":"Guido Francini","is_ca":true},{"name":"Lois E. Shepherd","is_ca":true},{"name":"Jean François Seitz","is_ca":true},{"name":"Roberto Labianca","is_ca":true},{"name":"Wei Chen","is_ca":true},{"name":"Michael P. Heldebrant","is_ca":true},{"name":"Richard M. Goldberg","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09422666171105251,"gpt":0.4446239429035839,"spread":0.3503972811925314,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02259993,0.001787585,0.009275442,0.001482389,0.0002051193,0.001572393,0.0007147609,0.001148092,0.001445683],"category_scores_gemma":[0.03162662,0.0006139577,0.01842646,0.001351704,0.0004647118,0.0009622356,0.0009366441,0.0008180711,0.0001696214],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008327711,"about_ca_system_score_gemma":0.0008325109,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001777808,"about_ca_topic_score_gemma":0.002390951,"domain_scores_codex":[0.9823184,0.01400834,0.001276955,0.001232949,0.0008303687,0.0003329989],"domain_scores_gemma":[0.9830928,0.01106097,0.003015092,0.001969867,0.000539076,0.0003221808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.1103641,0.0003097218,0.08713816,0.009413891,0.7165267,0.0001778545,0.0001260903,0.009046695,0.003410947,0.0003424297,0.001537975,0.06160535],"study_design_scores_gemma":[0.01481588,0.01736833,0.163607,0.001314145,0.7807623,0.0003045927,0.0001983244,0.01163853,0.003446446,0.002311279,0.004073344,0.0001597961],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7113671,0.2621447,0.01641689,0.001272298,0.0006289243,0.0009584542,0.00538413,0.0002126112,0.001614865],"genre_scores_gemma":[0.9864287,0.00772685,0.002958714,0.0004093037,0.0002084761,0.0002889076,0.001690406,0.00002671081,0.0002619881],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02259993,"threshold_uncertainty_score":0.1195213,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2983284890","doi":"10.1200/jco.19.02107","title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1014,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Pembrolizumab; Cohort; Colorectal cancer; Tolerability; Oncology; Microsatellite instability; Irinotecan; Progression-free survival; Clinical endpoint; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Cancer; Surgery; Phases of clinical research; Adverse effect; Chemotherapy; Clinical trial; Immunotherapy","authors":[{"name":"Dung T. Le","is_ca":false},{"name":"Tae Won Kim","is_ca":false},{"name":"Eric Van Cutsem","is_ca":false},{"name":"Ravit Geva","is_ca":false},{"name":"Dirk Jäger","is_ca":false},{"name":"Hiroki Hara","is_ca":false},{"name":"Matthew Burge","is_ca":false},{"name":"Bert H. O’Neil","is_ca":false},{"name":"Petr Kavan","is_ca":true},{"name":"Takayuki Yoshino","is_ca":false},{"name":"Rosine Guimbaud","is_ca":false},{"name":"Hiroya Taniguchi","is_ca":false},{"name":"Elena Élez","is_ca":false},{"name":"Salah‐Eddin Al‐Batran","is_ca":false},{"name":"Patrick M. Boland","is_ca":false},{"name":"Todd S. Crocenzi","is_ca":false},{"name":"Chloé E. Atreya","is_ca":false},{"name":"Yi Cui","is_ca":false},{"name":"Tong Dai","is_ca":false},{"name":"Patricia Marinello","is_ca":false},{"name":"Luis A. Díaz","is_ca":false},{"name":"Thierry André","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1353295079761783,"gpt":0.4909100416450203,"spread":0.355580533668842,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001721942,0.001265942,0.001209894,0.0003295442,0.0003947412,0.0007040731,0.0007303903,0.0008758027,0.003805772],"category_scores_gemma":[0.0007773715,0.000513775,0.0006159067,0.0003425473,0.000604491,0.0007691372,0.0003459552,0.002154334,0.0008366777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008700805,"about_ca_system_score_gemma":0.001720747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007652747,"about_ca_topic_score_gemma":0.00246127,"domain_scores_codex":[0.9996578,0.0001663437,0.00002009843,0.00005833765,0.00004439436,0.00005300025],"domain_scores_gemma":[0.9993281,0.00007218629,0.000189984,0.00005556722,0.0000549024,0.000299219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6206783,0.1596224,0.01578213,0.001429441,0.001285406,0.0004088887,0.0003678854,0.002559752,0.1016043,0.0003984135,0.006285326,0.08957777],"study_design_scores_gemma":[0.5682686,0.4065216,0.01452614,0.00005431264,0.0002817709,0.0003708089,0.00007481747,0.001060247,0.005681141,0.0001614421,0.002972342,0.00002677658],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924729,0.001046726,0.0006546027,0.0001947649,0.00006680626,0.003531298,0.0009472016,0.00006845982,0.00101725],"genre_scores_gemma":[0.9873806,0.001245069,0.00262605,0.0006539822,0.0001441664,0.003812736,0.002057067,0.00002213898,0.002058163],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003805772,"threshold_uncertainty_score":0.01273161,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2904444972","doi":"10.1200/jco.2018.78.2276","title":"T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":992,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Clinical endpoint; Cancer; Response Evaluation Criteria in Solid Tumors; Lung cancer; KRAS; Clinical trial; Phases of clinical research; Immunotherapy; Colorectal cancer","authors":[{"name":"Patrick A. Ott","is_ca":false},{"name":"Yung‐Jue Bang","is_ca":false},{"name":"Sarina A. Piha‐Paul","is_ca":false},{"name":"Albiruni R. Abdul Razak","is_ca":true},{"name":"Jaafar Bennouna","is_ca":false},{"name":"Jean‐Charles Soria","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Roger B. Cohen","is_ca":false},{"name":"Bert H. O’Neil","is_ca":false},{"name":"Janice M. Mehnert","is_ca":false},{"name":"Juanita Lopez","is_ca":false},{"name":"Toshihiko Doi","is_ca":false},{"name":"Emilie M.J. van Brummelen","is_ca":false},{"name":"Răzvan Cristescu","is_ca":false},{"name":"Ping Yang","is_ca":false},{"name":"Kenneth Emancipator","is_ca":false},{"name":"Karen Stein","is_ca":false},{"name":"Mark Ayers","is_ca":false},{"name":"Andrew K. Joe","is_ca":false},{"name":"Jared Lunceford","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0401353546324534,"gpt":0.3951411541431732,"spread":0.3550057995107199,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002899431,0.0005764595,0.0007286699,0.0004366727,0.0002713946,0.0007400503,0.0004577143,0.0004320864,0.001311856],"category_scores_gemma":[0.002323773,0.0002932235,0.0007146837,0.0005153617,0.0004364856,0.000613757,0.0006185006,0.0008795476,0.0002724506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005986908,"about_ca_system_score_gemma":0.0006314291,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003225736,"about_ca_topic_score_gemma":0.0005926365,"domain_scores_codex":[0.999087,0.0003143636,0.00009754535,0.0002534379,0.0001693056,0.00007826591],"domain_scores_gemma":[0.9981765,0.0003507059,0.0008819916,0.000143246,0.0001349366,0.0003126778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1256521,0.003614902,0.8068542,0.000320344,0.002049848,0.0001017217,0.0002021641,0.001778014,0.0206212,0.0001058761,0.001023169,0.03767634],"study_design_scores_gemma":[0.01617576,0.04931613,0.9166377,0.00006788305,0.002053474,0.0008513772,0.0001539946,0.004822649,0.006958862,0.0002603678,0.002657873,0.00004394096],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986488,0.0004629308,0.0001041553,0.00003780443,0.000004755003,0.00008121085,0.0003529451,0.000006373568,0.0003009323],"genre_scores_gemma":[0.9988062,0.0001274319,0.0002043897,0.00005641946,0.00001180631,0.00006372552,0.0006180947,0.000002647263,0.0001091841],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002899431,"threshold_uncertainty_score":0.01533377,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139891818","doi":"10.1200/jco.2011.38.0402","title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":990,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Seagen (Canada)","funders":"Takeda Oncology","keywords":"Brentuximab vedotin; Medicine; Anaplastic large-cell lymphoma; Internal medicine; Neutropenia; Antibody-drug conjugate; Phases of clinical research; Refractory (planetary science); Oncology; CD30; Adverse effect; Lymphoma; Gastroenterology; Chemotherapy; Immunology; Antibody; Monoclonal antibody","authors":[{"name":"Barbara Pro","is_ca":false},{"name":"Ranjana H. Advani","is_ca":false},{"name":"Pauline Brice","is_ca":false},{"name":"Nancy L. Bartlett","is_ca":false},{"name":"Joseph D. Rosenblatt","is_ca":false},{"name":"Tim Illidge","is_ca":false},{"name":"Jeffrey Matous","is_ca":false},{"name":"Radhakrishnan Ramchandren","is_ca":false},{"name":"Michelle A. Fanale","is_ca":false},{"name":"Joseph M. Connors","is_ca":false},{"name":"Yin Yang","is_ca":true},{"name":"Eric L. Sievers","is_ca":true},{"name":"Dana A. Kennedy","is_ca":true},{"name":"Andrei R. Shustov","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05924066866749524,"gpt":0.4100624161401102,"spread":0.350821747472615,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001427329,0.000716144,0.001107587,0.0001726331,0.0001891342,0.000515204,0.0003303558,0.0005468331,0.000836938],"category_scores_gemma":[0.0007443147,0.0002450716,0.0005913233,0.0002237481,0.0004199214,0.0003468338,0.0001473533,0.0009937803,0.000317303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003841491,"about_ca_system_score_gemma":0.0005676245,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005747862,"about_ca_topic_score_gemma":0.001005954,"domain_scores_codex":[0.99966,0.0001676142,0.00002510164,0.00005528369,0.00004714872,0.00004471881],"domain_scores_gemma":[0.9994911,0.0001088814,0.00009320172,0.00004038354,0.0000350141,0.0002313762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3532468,0.05704103,0.1049524,0.001516199,0.003121138,0.001799448,0.001142903,0.005003355,0.1460038,0.0002205196,0.004858246,0.3210942],"study_design_scores_gemma":[0.2763712,0.5452787,0.1594289,0.00009642788,0.00129613,0.002188366,0.0001663924,0.003232045,0.006875992,0.0001344967,0.004885307,0.00004607195],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967389,0.00207969,0.000190056,0.00009827822,0.0000219261,0.0002482471,0.0001479357,0.0000314108,0.0004434643],"genre_scores_gemma":[0.9967592,0.001220717,0.0005135837,0.0002859266,0.00005578731,0.0001867972,0.0006717365,0.000008085171,0.0002981125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001427329,"threshold_uncertainty_score":0.007548511,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2145304413","doi":"10.1200/jco.2005.09.137","title":"Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":989,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; International Prognostic Index; Internal medicine; Vincristine; Diffuse large B-cell lymphoma; Prednisone; CHOP; Population; Cyclophosphamide; Lymphoma; Gastroenterology; Oncology; Surgery; Chemotherapy","authors":[{"name":"Laurie H. Sehn","is_ca":true},{"name":"Jane Donaldson","is_ca":true},{"name":"Mukesh Chhanabhai","is_ca":true},{"name":"C. P. Fitzgerald","is_ca":true},{"name":"Karamjit Gill","is_ca":true},{"name":"Richard Klasa","is_ca":true},{"name":"Nicol Macpherson","is_ca":true},{"name":"John J. Spinelli","is_ca":true},{"name":"Judy Sutherland","is_ca":true},{"name":"Kenneth S. Wilson","is_ca":true},{"name":"Randy D. Gascoyne","is_ca":true},{"name":"Joseph M. Connors","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04227816456457361,"gpt":0.3824355696899724,"spread":0.3401574051253988,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000338467,0.0002080612,0.0002565586,0.0002570522,0.0005197587,0.0004969887,0.0003510281,0.0002628904,0.0007937143],"category_scores_gemma":[0.001041579,0.0001106308,0.0001466431,0.0004026437,0.0002889054,0.0001096846,0.0003423103,0.0003539594,0.0001139334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003695519,"about_ca_system_score_gemma":0.003313415,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.4809956,"about_ca_topic_score_gemma":0.6808133,"domain_scores_codex":[0.9997497,0.0000624783,0.00001324998,0.00004031541,0.00007461239,0.00005968348],"domain_scores_gemma":[0.9995784,0.00005894093,0.00007649093,0.00001899417,0.0001072141,0.0001598649],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002278335,0.0004475498,0.9462463,0.00009245962,0.00019222,0.0009874743,0.0002621847,0.0006475314,0.003759297,0.00005172895,0.00216812,0.04286678],"study_design_scores_gemma":[0.0001295997,0.0005080844,0.996444,0.00002703664,0.00008434037,0.0004887984,0.0001815927,0.000592146,0.0003157717,0.00001788704,0.00120277,0.000007901392],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985614,0.000455982,0.00003403955,0.0001104721,0.000006849165,0.00001000871,0.0001028143,0.000007282074,0.0007109631],"genre_scores_gemma":[0.9987724,0.0002781061,0.00006752516,0.0001039516,0.000006310195,0.000004111801,0.0002223996,0.000002155234,0.0005428978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5190043,"threshold_uncertainty_score":0.9563918,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2885107163","doi":"10.1200/jco.2018.79.1483","title":"Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":978,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Hazard ratio; Surgery; Esophagectomy; Clinical endpoint; Radiation therapy; Chemoradiotherapy; Esophagus; Neoadjuvant therapy; Neutropenia; Leukopenia; Phases of clinical research; Esophageal cancer; Gastroenterology; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Confidence interval","authors":[{"name":"Hong Yang","is_ca":true},{"name":"Hui Liu","is_ca":true},{"name":"Yuping Chen","is_ca":true},{"name":"Chengchu Zhu","is_ca":true},{"name":"Wentao Fang","is_ca":true},{"name":"Zhentao Yu","is_ca":true},{"name":"Weimin Mao","is_ca":true},{"name":"Jiaqing Xiang","is_ca":true},{"name":"Yongtao Han","is_ca":true},{"name":"Zhijian Chen","is_ca":true},{"name":"Haihua Yang","is_ca":true},{"name":"Jiaming Wang","is_ca":true},{"name":"Qingsong Pang","is_ca":true},{"name":"Xiao Zheng","is_ca":true},{"name":"Huanjun Yang","is_ca":true},{"name":"Tao Li","is_ca":true},{"name":"Florian Lordick","is_ca":true},{"name":"Xavier Benoît D’Journo","is_ca":true},{"name":"Robert J. Cerfolio","is_ca":true},{"name":"Robert J. Korst","is_ca":true},{"name":"Nuria Novoa","is_ca":true},{"name":"Scott J. Swanson","is_ca":true},{"name":"Alessandro Brunelli","is_ca":true},{"name":"Mahmoud Ismail","is_ca":true},{"name":"Hiran C. Fernando","is_ca":true},{"name":"Xu Zhang","is_ca":true},{"name":"Qun Li","is_ca":true},{"name":"Geng Wang","is_ca":true},{"name":"Baofu Chen","is_ca":true},{"name":"Teng Mao","is_ca":true},{"name":"Min Kong","is_ca":true},{"name":"Xufeng Guo","is_ca":true},{"name":"Ting Lin","is_ca":true},{"name":"Mengzhong Liu","is_ca":true},{"name":"Jianhua Fu","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1956553790038129,"gpt":0.5140244621430774,"spread":0.3183690831392645,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00242283,0.001960276,0.002740355,0.0004645652,0.0003857505,0.0009214709,0.001035931,0.001777635,0.004742248],"category_scores_gemma":[0.001338519,0.000667243,0.001641745,0.0004912629,0.001490723,0.001051141,0.0004247406,0.002481767,0.0007953634],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007170372,"about_ca_system_score_gemma":0.001406791,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006803822,"about_ca_topic_score_gemma":0.002155094,"domain_scores_codex":[0.9992435,0.0004917036,0.00003586478,0.00009559429,0.00004133554,0.00009201792],"domain_scores_gemma":[0.9989954,0.0002540419,0.0002282748,0.00008048415,0.0000464211,0.0003953681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9701658,0.01648676,0.0005544547,0.0002574296,0.0003688289,0.00003053667,0.00003588617,0.0003692593,0.003276362,0.00006250029,0.0004671376,0.007924993],"study_design_scores_gemma":[0.8385908,0.1587643,0.0009801926,0.00001929386,0.0002268814,0.00002994122,0.00001780654,0.0005247308,0.0004880003,0.00008065247,0.000265319,0.00001210261],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934345,0.001312368,0.0003959946,0.0004377609,0.0003778061,0.002728674,0.0004326004,0.00006857551,0.000811737],"genre_scores_gemma":[0.9854373,0.001841589,0.001761671,0.001236838,0.000586467,0.005772196,0.0007681765,0.00001846961,0.002577209],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004742248,"threshold_uncertainty_score":0.01586437,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2159862107","doi":"10.1200/jco.2011.41.0985","title":"Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":973,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Terry Fox Foundation; Michael Smith Health Research BC","keywords":"Vincristine; Medicine; Chromosomal translocation; International Prognostic Index; Immunohistochemistry; Rituximab; Lymphoma; Cyclophosphamide; Prednisone; Diffuse large B-cell lymphoma; Cancer research; CHOP; Internal medicine; Oncology; Cohort; Immunophenotyping; Pathology; Chemotherapy; Immunology; Flow cytometry; Biology; Gene","authors":[{"name":"Nathalie A. Johnson","is_ca":false},{"name":"Graham W. Slack","is_ca":false},{"name":"Kerry J. Savage","is_ca":false},{"name":"Joseph M. Connors","is_ca":false},{"name":"Susana Ben‐Neriah","is_ca":false},{"name":"Sanja Rogić","is_ca":false},{"name":"David W. Scott","is_ca":false},{"name":"King Tan","is_ca":false},{"name":"Christian Steidl","is_ca":false},{"name":"Laurie H. Sehn","is_ca":false},{"name":"Wing C. Chan","is_ca":false},{"name":"Javeed Iqbal","is_ca":false},{"name":"Paul N. Meyer","is_ca":false},{"name":"Georg Lenz","is_ca":false},{"name":"George W. Wright","is_ca":false},{"name":"Lisa M. Rimsza","is_ca":false},{"name":"Carlo Valentino","is_ca":false},{"name":"Patrick Brunhoeber","is_ca":false},{"name":"Thomas M. Grogan","is_ca":false},{"name":"Rita M. Braziel","is_ca":false},{"name":"James R. Cook","is_ca":false},{"name":"Raymond R. Tubbs","is_ca":false},{"name":"Dennis D. Weisenburger","is_ca":false},{"name":"Elı́as Campo","is_ca":false},{"name":"Andreas Rosenwald","is_ca":false},{"name":"German Ott","is_ca":false},{"name":"Jan Delabie","is_ca":false},{"name":"Christina Holcroft","is_ca":false},{"name":"Elaine S. Jaffe","is_ca":false},{"name":"Louis M. Staudt","is_ca":false},{"name":"Randy D. Gascoyne","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04353290157636887,"gpt":0.3813756691600561,"spread":0.3378427675836872,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003256015,0.000195099,0.0003083137,0.0003956283,0.0003016047,0.0003654283,0.0002271921,0.0002402114,0.0004938163],"category_scores_gemma":[0.000962871,0.0002248775,0.0002295104,0.000328892,0.000301887,0.000209397,0.0002914698,0.0003613723,0.0001178452],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003912305,"about_ca_system_score_gemma":0.0002644937,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001545683,"about_ca_topic_score_gemma":0.002515558,"domain_scores_codex":[0.9997543,0.00005633133,0.00002154824,0.0000675976,0.00005975273,0.00004057224],"domain_scores_gemma":[0.9995987,0.0001034679,0.0001157049,0.00003023004,0.00003320643,0.0001187298],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006296638,0.00006051567,0.9933761,0.0000107599,0.00004777496,0.0004127576,0.00006860431,0.00005955287,0.002848839,0.000008517835,0.00005538574,0.00242157],"study_design_scores_gemma":[0.00006899345,0.0004780821,0.995021,0.000006078215,0.00007434381,0.002740208,0.0001195746,0.0004889105,0.000747848,0.00001875044,0.0002313312,0.000004909841],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9997637,0.0001159463,0.00002752206,0.00000712837,0.000001914386,0.000002270204,0.00002106458,0.000001391704,0.00005906998],"genre_scores_gemma":[0.9997892,0.0000456729,0.00003175958,0.00000975541,0.00000420916,0.000002399913,0.00008982278,6.09031e-7,0.00002670872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001545683,"threshold_uncertainty_score":0.003073335,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387865238","doi":"10.1200/jco.23.02005","title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":931,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Takeda Oncology; Genentech; Menarini Group; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; Jounce Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; AstraZeneca; Novocure; Eisai Canada; Cholangiocarcinoma Foundation; F. Hoffmann-La Roche; Taiho Pharmaceutical; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Regeneron Pharmaceuticals; European Organisation for Research and Treatment of Cancer; Mersana Therapeutics; Karyopharm Therapeutics; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Trastuzumab; Immunohistochemistry; Clinical endpoint; Gastroenterology; Oncology; Surgery; Cancer; Breast cancer; Clinical trial","authors":[{"name":"Funda Meric‐Bernstam","is_ca":false},{"name":"Vicky Makker","is_ca":false},{"name":"Ana Oaknin","is_ca":false},{"name":"Do‐Youn Oh","is_ca":false},{"name":"Susana Banerjee","is_ca":false},{"name":"Antonio González-Martı́n","is_ca":false},{"name":"Kyung Hae Jung","is_ca":false},{"name":"Iwona Ługowska","is_ca":false},{"name":"Luís Manso","is_ca":false},{"name":"Aránzazu Manzano","is_ca":false},{"name":"Bohuslav Melichar","is_ca":false},{"name":"Salvatore Siena","is_ca":false},{"name":"Daniil Stroyakovskiy","is_ca":false},{"name":"Anitra Fielding","is_ca":false},{"name":"Yan Ma","is_ca":false},{"name":"Soham D. Puvvada","is_ca":false},{"name":"Norah J. Shire","is_ca":false},{"name":"Jung‐Yun Lee","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.161277714946747,"gpt":0.5034432526818972,"spread":0.3421655377351502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001753727,0.0007219521,0.001048108,0.0001923382,0.0002082547,0.0007142502,0.0003011519,0.0004724509,0.001331609],"category_scores_gemma":[0.0009854683,0.0001985958,0.0008045186,0.000229382,0.0004040637,0.0004321389,0.0002087087,0.001243649,0.0002627854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007933261,"about_ca_system_score_gemma":0.0006857576,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005699217,"about_ca_topic_score_gemma":0.001412263,"domain_scores_codex":[0.9996344,0.0001918287,0.00002615789,0.00004969072,0.00004690533,0.00005093066],"domain_scores_gemma":[0.9993641,0.0001542992,0.0001861008,0.00003419631,0.00004058596,0.000220743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7206991,0.01691626,0.06368087,0.0008715129,0.003111296,0.0004351881,0.0003470696,0.004293877,0.01873009,0.0002279227,0.007141156,0.1635456],"study_design_scores_gemma":[0.5305281,0.2918528,0.1554397,0.0001533074,0.002070789,0.001327893,0.0001391369,0.004300943,0.006132687,0.0003758319,0.007628632,0.00005017705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957266,0.002362277,0.0001447085,0.0001997704,0.00002827336,0.0002061637,0.0004508233,0.00002083636,0.0008605513],"genre_scores_gemma":[0.9960141,0.0009512624,0.0002447498,0.0002861237,0.00006782632,0.0001650526,0.001607505,0.000007601097,0.0006558032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001753727,"threshold_uncertainty_score":0.009274721,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2018038855","doi":"10.1200/jco.2006.09.5281","title":"Palliative Radiotherapy Trials for Bone Metastases: A Systematic Review","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":909,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Meta-analysis; Radiation therapy; Odds ratio; Internal medicine; Palliative care; Forest plot; Pathological; Surgery","authors":[{"name":"Edward Chow","is_ca":true},{"name":"Kristin Harris","is_ca":true},{"name":"Grace Fan","is_ca":true},{"name":"May Tsao","is_ca":true},{"name":"W.M. Sze","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.6544507210468016,"gpt":0.6580509111508396,"spread":0.003600190104038004,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02091992,0.002426997,0.01932047,0.00649211,0.0005766266,0.003204566,0.002136234,0.002131711,0.004707287],"category_scores_gemma":[0.06435921,0.001508267,0.02243912,0.006800446,0.0008967175,0.002143084,0.001496546,0.00184634,0.0003939359],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003763248,"about_ca_system_score_gemma":0.006295039,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004945341,"about_ca_topic_score_gemma":0.01392416,"domain_scores_codex":[0.979759,0.01167087,0.004818864,0.001189081,0.002197716,0.0003644474],"domain_scores_gemma":[0.9539312,0.03524745,0.007194801,0.0008889092,0.002378204,0.0003595767],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0008677492,0.00001822379,0.0008351165,0.8408327,0.1406344,0.000078688,0.00006617744,0.000228482,0.0001215141,0.0001673813,0.0008848325,0.01526479],"study_design_scores_gemma":[0.001709444,0.0004629571,0.003313905,0.3302363,0.6560775,0.0002396083,0.000103955,0.0002024775,0.0001777259,0.0004782535,0.006958946,0.00003897791],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001150549,0.997417,0.0002810837,0.0002277836,0.000155815,0.0003828391,0.0002077289,0.00001566208,0.0001615474],"genre_scores_gemma":[0.04769,0.9466118,0.001885074,0.001434788,0.0002816893,0.001584003,0.0003132988,0.00002422063,0.000175136],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02091992,"threshold_uncertainty_score":0.1106364,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2155012968","doi":"10.1200/jco.2008.16.9847","title":"Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":908,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Internal medicine; Renal cell carcinoma; Clinical endpoint; Hazard ratio; Gastroenterology; Proteinuria; Oncology; Surgery; Randomized controlled trial; Chemotherapy; Confidence interval; Kidney","authors":[{"name":"Brian I. Rini","is_ca":true},{"name":"Susan Halabi","is_ca":true},{"name":"Jonathan E. Rosenberg","is_ca":true},{"name":"Walter M. Stadler","is_ca":true},{"name":"Daniel A. Vaena","is_ca":true},{"name":"San-San Ou","is_ca":true},{"name":"Laura Archer","is_ca":true},{"name":"James N. Atkins","is_ca":true},{"name":"Joel Picus","is_ca":true},{"name":"Piotr Czaykowski","is_ca":true},{"name":"Janice P. Dutcher","is_ca":true},{"name":"Eric J. Small","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0995623420053774,"gpt":0.3685206473544246,"spread":0.2689583053490472,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002443662,0.0006744482,0.00264817,0.0003763046,0.0003578893,0.0007786211,0.0006373534,0.0008808518,0.002416384],"category_scores_gemma":[0.00289114,0.0004273332,0.001800217,0.0005311111,0.0004811411,0.0004013324,0.0004566677,0.001844264,0.0003378572],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001860825,"about_ca_system_score_gemma":0.002136664,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009755515,"about_ca_topic_score_gemma":0.01989873,"domain_scores_codex":[0.999041,0.0005703272,0.00005646126,0.0001217117,0.0001232579,0.00008714919],"domain_scores_gemma":[0.9989682,0.0002579297,0.0003363203,0.00004527504,0.00007337253,0.000318855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9184204,0.004132637,0.009165103,0.000692402,0.003179527,0.00006879352,0.0001046564,0.001670444,0.002504624,0.0000908803,0.003589493,0.05638093],"study_design_scores_gemma":[0.8229398,0.1134048,0.04971293,0.0002656664,0.005669423,0.0002046755,0.00007663694,0.003903236,0.0007635197,0.0001899822,0.002822121,0.00004727692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876119,0.007836751,0.0001767191,0.001555562,0.0002760443,0.0005100945,0.0005037098,0.00006345556,0.001465714],"genre_scores_gemma":[0.9913265,0.003596921,0.0007408162,0.001528527,0.0002659802,0.0004695219,0.001153535,0.00001080356,0.0009073316],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009755515,"threshold_uncertainty_score":0.0193975,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162605078","doi":"10.1200/jco.2004.06.082","title":"Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":895,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Radiation therapy; Randomization; Quality of life (healthcare); Internal medicine; Wilcoxon signed-rank test; Glioblastoma; Clinical endpoint; Randomized controlled trial; Survival analysis; Surgery; Prospective cohort study; Mann–Whitney U test","authors":[{"name":"Wilson Roa","is_ca":true},{"name":"Penny Brasher","is_ca":true},{"name":"Glenn Bauman","is_ca":true},{"name":"Margaret Anthes","is_ca":true},{"name":"Éduardo Bruera","is_ca":true},{"name":"A. Chan","is_ca":true},{"name":"B. Fisher","is_ca":true},{"name":"Dorcas Fulton","is_ca":true},{"name":"Sunil Gulavita","is_ca":true},{"name":"Chuan‐Ming Hao","is_ca":true},{"name":"Salina Husain","is_ca":true},{"name":"Albert Murtha","is_ca":true},{"name":"Kenneth C. Petruk","is_ca":true},{"name":"Donna E. Stewart","is_ca":true},{"name":"Peter Tai","is_ca":true},{"name":"Raul C. Urtasun","is_ca":true},{"name":"J. G. Cairncross","is_ca":true},{"name":"Peter Forsyth","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04764455615456314,"gpt":0.4428320914777188,"spread":0.3951875353231556,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002173284,0.0007171261,0.002060492,0.0002511056,0.0003461091,0.0006939281,0.0005246811,0.001138034,0.003083615],"category_scores_gemma":[0.002513584,0.0003613373,0.001545819,0.0003580352,0.0006498989,0.0006814753,0.0003644177,0.001787852,0.0003155118],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000530595,"about_ca_system_score_gemma":0.0009231656,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006653193,"about_ca_topic_score_gemma":0.001378191,"domain_scores_codex":[0.9989562,0.0005969128,0.0001239397,0.0001706677,0.00006590541,0.00008643528],"domain_scores_gemma":[0.9982716,0.0004036762,0.0006212463,0.0001220152,0.00008092888,0.0005005343],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9765469,0.004217708,0.002896857,0.0004308418,0.001015666,0.00002915367,0.00002643851,0.0002995469,0.0009350584,0.00007363864,0.0002657209,0.01326242],"study_design_scores_gemma":[0.8445761,0.139898,0.01253233,0.00007899274,0.001051037,0.00007247723,0.00002374619,0.0006159149,0.0002081422,0.0001671736,0.0007561277,0.0000200528],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938762,0.0036763,0.000234033,0.000332575,0.0002815972,0.0009498878,0.0002158599,0.00001607135,0.0004174955],"genre_scores_gemma":[0.9932562,0.002087135,0.0008548959,0.0007878389,0.0003860478,0.001732261,0.000459139,0.000004266475,0.000432205],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003083615,"threshold_uncertainty_score":0.01149356,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}